<SEC-DOCUMENT>0001628280-23-014759.txt : 20230502
<SEC-HEADER>0001628280-23-014759.hdr.sgml : 20230502
<ACCEPTANCE-DATETIME>20230502080553
ACCESSION NUMBER:		0001628280-23-014759
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20230502
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230502
DATE AS OF CHANGE:		20230502

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PFIZER INC
		CENTRAL INDEX KEY:			0000078003
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				135315170
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-03619
		FILM NUMBER:		23876685

	BUSINESS ADDRESS:	
		STREET 1:		66 HUDSON BOULEVARD EAST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10001-2192
		BUSINESS PHONE:		2127332323

	MAIL ADDRESS:	
		STREET 1:		66 HUDSON BOULEVARD EAST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10001-2192

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PFIZER CHARLES & CO INC
		DATE OF NAME CHANGE:	19710908
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>pfe-20230502.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:3bfb6b0d-6e8d-4cb0-a62e-0371898ecb32,g:1009c864-99f1-4bb4-ae0b-fc6fb1dc1c0e,d:db47b45ae2a54ced85b4748bf789ed3d--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:pfe="http://www.pfizer.com/20230502" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>pfe-20230502</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF80L2ZyYWc6MjczOGFjNjlkZDFkNGI5NTg5NjQ2MjdhODUwZmYxOTcvdGFibGU6NDJjM2MyYjc1OWI0NDg0YmEwOTQ5MDg3YzgxODg5MzkvdGFibGVyYW5nZTo0MmMzYzJiNzU5YjQ0ODRiYTA5NDkwODdjODE4ODkzOV8xLTEtMS0xLTYxNDg4Nw_02b8d0dc-e690-4599-9544-e85b50bf1046">0000078003</ix:nonNumeric><ix:nonNumeric contextRef="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF80L2ZyYWc6MjczOGFjNjlkZDFkNGI5NTg5NjQ2MjdhODUwZmYxOTcvdGFibGU6NDJjM2MyYjc1OWI0NDg0YmEwOTQ5MDg3YzgxODg5MzkvdGFibGVyYW5nZTo0MmMzYzJiNzU5YjQ0ODRiYTA5NDkwODdjODE4ODkzOV8yLTEtMS0xLTYxNDg4Nw_b14d2887-eb2f-458a-bb02-6d2f26d05110">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="pfe-20230502.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-02</xbrli:startDate><xbrli:endDate>2023-05-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebb1578a148d4edf8114dad39708811d_D20230502-20230502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-02</xbrli:startDate><xbrli:endDate>2023-05-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ad3ddec41e540859df4e6108778cc03_D20230502-20230502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pfe:NotesDue20271.000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-02</xbrli:startDate><xbrli:endDate>2023-05-02</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="idb47b45ae2a54ced85b4748bf789ed3d_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Washington, D.C.&#160;&#160;20549</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGV4dHJlZ2lvbjplYzhjNThmMWNmZDM0YmQwYjMyN2ExNjVhMjM2ZjcyNV8yNzgw_470ac897-3acf-469f-b3ba-6dfe474e5034"><ix:nonNumeric contextRef="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGV4dHJlZ2lvbjplYzhjNThmMWNmZDM0YmQwYjMyN2ExNjVhMjM2ZjcyNV8yNzgw_af3d24b9-8345-4e39-b98d-8a108e6686bf">8-K</ix:nonNumeric></ix:nonNumeric> </span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CURRENT REPORT</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PURSUANT TO SECTION 13 OR 15(d) OF THE</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES EXCHANGE ACT OF 1934</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of report (Date of earliest event reported): <ix:nonNumeric contextRef="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGV4dHJlZ2lvbjplYzhjNThmMWNmZDM0YmQwYjMyN2ExNjVhMjM2ZjcyNV8yMjk_1c79eebe-e644-47b0-97a6-702ec00c65e4">May 2, 2023</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGV4dHJlZ2lvbjplYzhjNThmMWNmZDM0YmQwYjMyN2ExNjVhMjM2ZjcyNV8yNzgx_29813641-588e-4a78-a030-d865dd7e6199"><ix:nonNumeric contextRef="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGV4dHJlZ2lvbjplYzhjNThmMWNmZDM0YmQwYjMyN2ExNjVhMjM2ZjcyNV8yNzgx_4072a101-eff5-48d2-b455-67b0ab481bf4">PFIZER INC</ix:nonNumeric></ix:nonNumeric>.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.064%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.892%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGFibGU6MGI4NGFmOWU4ZDRmNGExZmE1NjAxNjdiYzRjMTk5ZmIvdGFibGVyYW5nZTowYjg0YWY5ZThkNGY0YTFmYTU2MDE2N2JjNGMxOTlmYl8wLTAtMS0xLTYxNDg4Nw_d558708d-7bc8-46fa-95e9-bd1bc8bc768a">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGFibGU6MGI4NGFmOWU4ZDRmNGExZmE1NjAxNjdiYzRjMTk5ZmIvdGFibGVyYW5nZTowYjg0YWY5ZThkNGY0YTFmYTU2MDE2N2JjNGMxOTlmYl8wLTEtMS0xLTYxNDg4Nw_45c2f30b-939c-41b5-8337-ac306f987816">1-3619</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGFibGU6MGI4NGFmOWU4ZDRmNGExZmE1NjAxNjdiYzRjMTk5ZmIvdGFibGVyYW5nZTowYjg0YWY5ZThkNGY0YTFmYTU2MDE2N2JjNGMxOTlmYl8wLTItMS0xLTYxNDg4Nw_15d6a986-283b-4dbe-8d98-fa09294099eb">13-5315170</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">jurisdiction of</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:197.25pt"><tr><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:64.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGFibGU6ZmJiOTUzYjUwOWU2NDYzMGFkMmZkNGI4YjU5NmUxZDQvdGFibGVyYW5nZTpmYmI5NTNiNTA5ZTY0NjMwYWQyZmQ0YjhiNTk2ZTFkNF8wLTAtMS0xLTYxNDg4Nw_dd13839d-bbb7-4091-b517-f65b7e0d894c">66 Hudson Boulevard East</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGFibGU6ZmJiOTUzYjUwOWU2NDYzMGFkMmZkNGI4YjU5NmUxZDQvdGFibGVyYW5nZTpmYmI5NTNiNTA5ZTY0NjMwYWQyZmQ0YjhiNTk2ZTFkNF8wLTItMS0xLTYxNDg4Nw_8851aff6-4e36-43f5-8c6c-7fe5bc9419af">10001-2192</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGFibGU6ZmJiOTUzYjUwOWU2NDYzMGFkMmZkNGI4YjU5NmUxZDQvdGFibGVyYW5nZTpmYmI5NTNiNTA5ZTY0NjMwYWQyZmQ0YjhiNTk2ZTFkNF8xLTAtMS0xLTYxNDg4Nw_cfd2e570-9e61-4224-8e0f-fb352e5c9b77">New York,</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGFibGU6ZmJiOTUzYjUwOWU2NDYzMGFkMmZkNGI4YjU5NmUxZDQvdGFibGVyYW5nZTpmYmI5NTNiNTA5ZTY0NjMwYWQyZmQ0YjhiNTk2ZTFkNF8xLTEtMS0xLTYxNDg4Nw_6f06eb59-f1af-4614-bbe1-a609b37da267">New York</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonNumeric contextRef="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGV4dHJlZ2lvbjplYzhjNThmMWNmZDM0YmQwYjMyN2ExNjVhMjM2ZjcyNV8yNzgy_cb34bfd8-cb8d-458f-8a3c-5e5d47d0bd51">212</ix:nonNumeric>) <ix:nonNumeric contextRef="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGV4dHJlZ2lvbjplYzhjNThmMWNmZDM0YmQwYjMyN2ExNjVhMjM2ZjcyNV8yNzc1_e1498378-d223-4b7e-8128-cf2a63b988be">733-2323</ix:nonNumeric> </span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGV4dHJlZ2lvbjplYzhjNThmMWNmZDM0YmQwYjMyN2ExNjVhMjM2ZjcyNV8yNzc2_9ff77caa-0ae0-4594-bad5-0fa8c8a9def4">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGV4dHJlZ2lvbjplYzhjNThmMWNmZDM0YmQwYjMyN2ExNjVhMjM2ZjcyNV8yNzgz_4b960350-1f1f-4fd3-b772-e16d9ad1af48">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGV4dHJlZ2lvbjplYzhjNThmMWNmZDM0YmQwYjMyN2ExNjVhMjM2ZjcyNV8yNzc4_42f5fede-151f-46d5-aa6c-373c2667f33e">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGV4dHJlZ2lvbjplYzhjNThmMWNmZDM0YmQwYjMyN2ExNjVhMjM2ZjcyNV8yNzc3_3c13b83f-dd9d-47f5-a5dd-cd15af8e3310">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.744%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.744%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iebb1578a148d4edf8114dad39708811d_D20230502-20230502" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGFibGU6NWQyZTA5NGQ3NDNjNDFhYzg4Y2ZjMDBhZDc1ZjliODYvdGFibGVyYW5nZTo1ZDJlMDk0ZDc0M2M0MWFjODhjZmMwMGFkNzVmOWI4Nl8zLTAtMS0xLTYxNDg4Nw_07671daa-7140-4c7e-8f28-67ecf8f59fb7">Common Stock, $0.05 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iebb1578a148d4edf8114dad39708811d_D20230502-20230502" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGFibGU6NWQyZTA5NGQ3NDNjNDFhYzg4Y2ZjMDBhZDc1ZjliODYvdGFibGVyYW5nZTo1ZDJlMDk0ZDc0M2M0MWFjODhjZmMwMGFkNzVmOWI4Nl8zLTItMS0xLTYxNDg4Nw_09fe4974-992d-4fbe-908e-9fe78c8ccdd5">PFE</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iebb1578a148d4edf8114dad39708811d_D20230502-20230502" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGFibGU6NWQyZTA5NGQ3NDNjNDFhYzg4Y2ZjMDBhZDc1ZjliODYvdGFibGVyYW5nZTo1ZDJlMDk0ZDc0M2M0MWFjODhjZmMwMGFkNzVmOWI4Nl8zLTQtMS0xLTYxNDg4Nw_05a7af27-9c11-474c-8bac-43c953ee2caf"><ix:nonNumeric contextRef="i3ad3ddec41e540859df4e6108778cc03_D20230502-20230502" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGFibGU6NWQyZTA5NGQ3NDNjNDFhYzg4Y2ZjMDBhZDc1ZjliODYvdGFibGVyYW5nZTo1ZDJlMDk0ZDc0M2M0MWFjODhjZmMwMGFkNzVmOWI4Nl8zLTQtMS0xLTYxNDg4Nw_efad3c18-987e-47ac-960b-5b92fc8ba0f3">New York Stock Exchange</ix:nonNumeric></ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3ad3ddec41e540859df4e6108778cc03_D20230502-20230502" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGFibGU6NWQyZTA5NGQ3NDNjNDFhYzg4Y2ZjMDBhZDc1ZjliODYvdGFibGVyYW5nZTo1ZDJlMDk0ZDc0M2M0MWFjODhjZmMwMGFkNzVmOWI4Nl80LTAtMS0xLTYxNDg4Nw_373c172f-9cbb-4f8c-89a5-c39392d123e5">1.000% Notes due 2027</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3ad3ddec41e540859df4e6108778cc03_D20230502-20230502" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGFibGU6NWQyZTA5NGQ3NDNjNDFhYzg4Y2ZjMDBhZDc1ZjliODYvdGFibGVyYW5nZTo1ZDJlMDk0ZDc0M2M0MWFjODhjZmMwMGFkNzVmOWI4Nl80LTItMS0xLTYxNDg4Nw_0bc78b3c-f1fa-4d4f-9242-8a574623939f">PFE27</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iebb1578a148d4edf8114dad39708811d_D20230502-20230502" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGFibGU6NWQyZTA5NGQ3NDNjNDFhYzg4Y2ZjMDBhZDc1ZjliODYvdGFibGVyYW5nZTo1ZDJlMDk0ZDc0M2M0MWFjODhjZmMwMGFkNzVmOWI4Nl80LTQtMS0xLTYxNDg4Nw_05a7af27-9c11-474c-8bac-43c953ee2caf"><ix:nonNumeric contextRef="i3ad3ddec41e540859df4e6108778cc03_D20230502-20230502" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGFibGU6NWQyZTA5NGQ3NDNjNDFhYzg4Y2ZjMDBhZDc1ZjliODYvdGFibGVyYW5nZTo1ZDJlMDk0ZDc0M2M0MWFjODhjZmMwMGFkNzVmOWI4Nl80LTQtMS0xLTYxNDg4Nw_efad3c18-987e-47ac-960b-5b92fc8ba0f3">New York Stock Exchange</ix:nonNumeric></ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </span></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company &#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGV4dHJlZ2lvbjplYzhjNThmMWNmZDM0YmQwYjMyN2ExNjVhMjM2ZjcyNV8yNzc5_95b74812-dc2d-4ae7-b4bb-727ecfe55e28">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02 Results of Operations and Financial Condition</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;2, 2023, Pfizer Inc. (&#8220;Pfizer&#8221;) issued a press release announcing its financial results for the first quarter of 2023. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information furnished pursuant to this &#8220;Item 2.02 - Results of Operations and Financial Condition&#8221;, including Exhibit 99, shall not be deemed to be &#8220;filed&#8221; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (&#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01 Financial Statements and Exhibits</span></div><div><span><br/></span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;Exhibits</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.989%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pfe-04022023xex99.htm">Exhibit 99</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Press Release of Pfizer Inc. dated <ix:nonNumeric contextRef="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGFibGU6MmY5YzNjZDc1ODNhNGRhMjkyY2JjNDg0OTJkZTZhZmUvdGFibGVyYW5nZToyZjljM2NkNzU4M2E0ZGEyOTJjYmM0ODQ5MmRlNmFmZV8yLTItMS0xLTYxODExOS90ZXh0cmVnaW9uOjRiMTVhMjU3ZjY5ZjQzMzZiNTUzMmY4YTBkYjhmYWIyXzU0OTc1NTgxNDA5OQ_1c79eebe-e644-47b0-97a6-702ec00c65e4">May 2, 2023</ix:nonNumeric>, reporting Pfizer&#8217;s financial results for the first quarter of 2023.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:14.852%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.210%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT INDEX</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pfe-04022023xex99.htm">99</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Press Release of Pfizer Inc. dated </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May&#160;2, 2023, reporting Pfizer&#8217;s financial</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">results for the first quarter of 2023.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:33.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:59.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PFIZER INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Margaret M. Madden</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Margaret M. Madden</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Corporate Secretary</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Governance Counsel</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: May&#160;2, 2023 </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>pfe-04022023xex99.htm
<DESCRIPTION>EX-99
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i3f14874d4dff44619437bc4e8219b905_1"></div><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Exhibit 99</font></div></div><div style="margin-top:6pt"><img alt="pfizerlogoa.jpg" src="pfizerlogoa.jpg" style="height:59px;margin-bottom:5pt;vertical-align:text-bottom;width:137px"></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pfizer Reports First-Quarter 2023 Results</font></div><div style="margin-bottom:3pt;margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9642;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.11pt">First-Quarter 2023 Revenues of $18.3 Billion</font></div><div style="margin-bottom:3pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.5pt">Expected Decline in Comirnaty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Revenue Drove 26% Operational Decrease in First-Quarter 2023 Revenues</font></div><div style="margin-bottom:3pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.5pt">First-Quarter 2023 Revenues from Comirnaty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and Paxlovid of $7.1 Billion</font></div><div style="margin-bottom:3pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.5pt">Excluding Contributions from Comirnaty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and Paxlovid, Revenues Grew 5% Operationally</font></div><div style="margin-bottom:3pt;margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9642;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.11pt">First-Quarter 2023 Reported Diluted EPS</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">(2)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of $0.97, a Year-Over-Year Decline of 29%, and Adjusted Diluted EPS</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">(3)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of $1.23, a Year-Over-Year Decline of 24%</font></div><div style="margin-bottom:3pt;margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9642;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.11pt">Pfizer Reaffirms Full-Year 2023 Financial Guidance</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">(4)</font></div><div style="margin-bottom:3pt;margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.11pt">Pfizer Continued to Make Significant Progress Toward an Unprecedented Number of Anticipated New Product and Indication Launches&#59; Milestones Include FDA Approvals for Zavzpret, Cibinqo for Adolescents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and Prevnar 20 in Pediatric Patients</font></div><div style="margin-top:21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">NEW YORK, NY, Tuesday, May&#160;2, 2023 &#8211; Pfizer Inc. (NYSE&#58; PFE) reported financial results for the first quarter of 2023</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> and reaffirmed full-year 2023 financial guidance. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">The first-quarter 2023 earnings presentation and accompanying prepared remarks from management as well as the quarterly update to Pfizer&#8217;s R&#38;D pipeline can be found at www.pfizer.com.</font></div><div id="i3f14874d4dff44619437bc4e8219b905_4"></div><div style="margin-bottom:6pt;margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">EXECUTIVE COMMENTARY</font></div><div style="margin-bottom:9pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Dr. Albert Bourla, Chairman and Chief Executive Officer, stated&#58; &#8220;This is an exciting time for Pfizer as we are already executing on and rigorously planning for an unprecedented number of anticipated new product and indication launches, most of which are expected to occur in the second half of 2023. We have made excellent progress toward this goal already this year with the U.S. approvals for Zavzpret, Cibinqo for adolescents and Prevnar 20 in pediatric patients, and regulatory filing acceptances for a Braftovi + Mektovi sNDA, sNDA for the Talzenna and Xtandi combination, elranatamab BLA and our RSV maternal vaccine candidate &#8212; which, if approved, would be the first vaccine for administration to pregnant individuals to help protect against the complications of RSV disease in infants from birth up to six months of age.</font></div><div style="margin-bottom:9pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">During the first quarter, we announced plans to advance the battle against cancer with a definitive agreement to acquire Seagen, a global biotechnology company that discovers, develops and commercializes transformative oncology medicines. By combining Seagen&#8217;s category-leading antibody-drug conjugate (ADC) technology with Pfizer&#8217;s scale, expertise and capabilities, we believe we can accelerate breakthroughs in cancer medicines and </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 1 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;margin-top:6pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">introduce new solutions to patients around the world. Oncology remains a core therapeutic area for Pfizer, and we believe the proposed acquisition will enhance our position in this important space. </font></div><div style="margin-bottom:9pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">We believe the strength of our in-line products and expected near-term launches and revenue contribution from business development activities, including the proposed acquisition of Seagen, will position Pfizer to deliver robust operational growth through 2025 and beyond.&#8221;</font></div><div style="margin-bottom:9pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">David Denton, Chief Financial Officer and Executive Vice President, stated&#58; &#8220;Our first-quarter results were in line with our expectations, underlining our continued confidence in achieving 7% to 9% operational revenue growth for fiscal-year 2023, excluding our COVID-19 products and anticipated foreign exchange impacts. We expect the majority of this growth to occur in the second half of 2023, given the timing of our expected near-term launches. Integration planning for our proposed acquisition of Seagen is underway, and we continue to expect the transaction to close in late 2023 or early 2024, subject to the satisfaction of customary closing conditions. As we de-lever our capital structure after the close, we expect our strong balance sheet will continue to provide the flexibility for future dividend increases and share repurchase activity, as well as additional business development activity.&#8221;</font></div><div id="i3f14874d4dff44619437bc4e8219b905_7"></div><div style="margin-bottom:6pt;margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Results for the first quarter of 2023 and 2022</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> are summarized below.</font></div><div style="margin-bottom:6pt;margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">OVERALL RESULTS</font></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.244%"><tr><td style="width:1.0%"></td><td style="width:43.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.489%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">($ in millions, except<br>per share amounts)</font></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First-Quarter</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</font></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;18,282&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;25,661&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29%)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported Net Income</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,543&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,864&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30%)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported Diluted EPS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.97&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.37&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29%)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Income</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,036&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,338&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25%)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Diluted EPS</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.23&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.62&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24%)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:13pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">REVENUES</font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.690%"><tr><td style="width:1.0%"></td><td style="width:44.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.152%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.152%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.985%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">($ in millions)</font></td><td colspan="12" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First-Quarter</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</font></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</font></td><td colspan="6" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% Change</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oper.</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Global Biopharmaceuticals Business (Biopharma)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</font></div></td><td colspan="2" style="border-top:1pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$&#160;17,971</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$&#160;25,323</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #6d6d6d;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(29%)</font></td><td colspan="3" style="border-top:1pt solid #6d6d6d;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(26%)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Primary Care</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</font></div></td><td colspan="2" style="border-top:1pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,505&#160;</font></td><td style="border-top:1pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,851&#160;</font></td><td style="border-top:1pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #6d6d6d;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39%)</font></td><td colspan="3" style="border-top:1pt solid #6d6d6d;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37%)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty Care</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,612&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,505&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,855&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,967&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1%)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Business Innovation</font></td><td colspan="2" style="border-top:1pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$&#160;310</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$&#160;338</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #6d6d6d;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8%)</font></td><td colspan="3" style="border-top:1pt solid #6d6d6d;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5%)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL REVENUES</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$&#160;18,282</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$&#160;25,661</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(29%)</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(26%)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 2 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><font><br></font></div></div><div style="margin-bottom:1pt;margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Beginning in the third quarter of 2022, Pfizer made several organizational changes to further transform its operations to better leverage its expertise in certain areas and in anticipation of potential future new product and indication launches. These changes included establishing a new commercial structure within Biopharma focused on three broad customer groups (primary care, specialty care and oncology)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">, optimizing Pfizer&#8217;s end-to-end R&#38;D operations and further prioritizing its internal R&#38;D portfolio, as well as realigning certain enabling and platform functions across the organization to ensure alignment with this new operating structure.</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">In addition, in the first quarter of 2023, Pfizer established an operating segment named Business Innovation that includes Pfizer CentreOne (PC1), the company&#8217;s global contract development and manufacturing organization and a leading supplier of specialty active pharmaceutical ingredients&#59; and Pfizer Ignite, a recently launched offering that provides strategic guidance and end-to-end R&#38;D services to select innovative biotech companies that align with Pfizer&#8217;s R&#38;D focus areas.</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Prior period amounts have been revised to conform to the current period presentation for all changes discussed above.</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Some amounts in this press release may not add due to rounding. All percentages have been calculated using unrounded amounts. References to operational variances pertain to period-over-period changes that exclude the impact of foreign exchange rates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(7)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">.</font></div><div id="i3f14874d4dff44619437bc4e8219b905_13"></div><div style="margin-bottom:6pt;margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">CAPITAL ALLOCATION</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">During the first three months of 2023, Pfizer deployed its capital in a variety of ways, which primarily include the following two categories&#58;</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:14.11pt">Reinvesting capital into initiatives intended to enhance the future growth prospects of the company, including $2.5 billion invested in internal research and development projects, and</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:14.11pt">Returning capital directly to shareholders through $2.3&#160;billion of cash dividends, or $0.41 per share of common stock. </font></div><div style="margin-bottom:9pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">No share repurchases have been completed to date in 2023. As of May&#160;2, 2023, Pfizer&#8217;s remaining share repurchase authorization is $3.3 billion. Current financial guidance does not anticipate any share repurchases in 2023.</font></div><div style="margin-bottom:9pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">First-quarter 2023 diluted weighted-average shares outstanding used to calculate Reported</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> and Adjusted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> diluted EPS were 5,727 million shares, a decrease of 31 million shares compared to the prior-year quarter, primarily due to shares repurchased in the first quarter of 2022, partially offset by shares issued for employee compensation programs. </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 3 -</font></div></div></div><div id="i3f14874d4dff44619437bc4e8219b905_10995116278429"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">2023 FINANCIAL GUIDANCE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:700;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(4)</font></div><div style="margin-bottom:6pt;margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Pfizer reaffirms all components of its full-year 2023 financial guidance, which is presented below. This guidance includes management&#8217;s expectations for contributions from the entire company, including Comirnaty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> and Paxlovid.</font></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023 Financial Guidance</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues*</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$67.0 to $71.0 billion</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Operational</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Growth&#47;(Decline) vs. Prior Year</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(33%) to (29%)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Growth&#47;(Decline) vs. Prior Year</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(33%) to (29%)</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> Diluted EPS*</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$3.25 to $3.45</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Operational</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Growth&#47;(Decline) vs. Prior Year</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(50%) to (47%)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Growth&#47;(Decline) vs. Prior Year</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(51%) to (48%)</font></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Changes in foreign exchange rates have had a minimal incremental impact since full-year 2023 guidance was issued. Please refer to Press Release Footnote (4) for additional information.</font></div><div style="margin-bottom:6pt;margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">The midpoint of the guidance range for revenues reflects a 31% operational decrease compared to 2022 revenues. Company revenues are anticipated to be lower in 2023 than in 2022 due entirely to expected revenue declines for Pfizer&#8217;s COVID-19 products.</font></div><div style="margin-bottom:6pt;margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Excluding COVID-19 products, the Company continues to expect 7% to 9% operational revenue growth in 2023.</font></div><div style="margin-bottom:6pt;margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Revenue guidance for Pfizer&#8217;s COVID-19 products is as follows&#58;</font></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:22.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:14.11pt">Comirnaty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> revenues of approximately $13.5&#160;billion, down 64% from 2022 results.</font></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:22.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:14.11pt">Paxlovid revenues of approximately $8&#160;billion, down 58% from 2022 results.</font></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:22.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:14.11pt">In contrast to previous years, guidance for both products is no longer based primarily on expected deliveries under existing signed or committed supply contracts, but now also includes, among other things, anticipated sales through traditional commercial markets in the U.S. in the second half of 2023.</font></div><div style="margin-bottom:6pt;margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">The midpoint of the guidance range for Adjusted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> diluted EPS reflects a 49% operational decrease compared to 2022, primarily driven by anticipated lower revenues from COVID-19 products, higher spending to support anticipated near-term launches and greater investment in certain late-stage pipeline projects.</font></div><div style="margin-bottom:6pt;margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Financial guidance for Adjusted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> diluted EPS is calculated using approximately 5.75 billion weighted average shares outstanding, and assumes no share repurchases in 2023.</font></div><div style="margin-bottom:6pt;margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Other components of Pfizer&#8217;s 2023 financial guidance are presented below.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 4 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:9pt"><font><br></font></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"></td><td style="width:49.199%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:48.601%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:30pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Adjusted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Cost of Sales as a Percentage of Revenues</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">28.0% to 30.0%</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:30pt"><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Adjusted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> SI&#38;A Expenses</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$13.8 to $14.8 billion</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:30pt"><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Adjusted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> R&#38;D Expenses</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$12.4 to $13.4 billion</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:30pt"><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Acquired IPR&#38;D Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Approximately $0.1 billion</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:30pt"><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Adjusted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Other (Income)&#47;Deductions</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Approximately $1.5 billion of income</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:30pt"><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Effective Tax Rate on Adjusted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Income</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Approximately 15.0%</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Pfizer&#8217;s 2023 financial guidance is based on estimates and assumptions that are subject to significant uncertainties, particularly with regard to the anticipated performance of Comirnaty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> and Paxlovid. See the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:174%">Overview of Our Performance, Operating Environment, Strategy and Outlook &#8212; The Global Economic Environment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> section of Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations in Pfizer&#8217;s 2022 Annual Report on Form 10-K and Pfizer&#8217;s fourth-quarter 2022 earnings press release (available at www.pfizer.com) for additional information.</font></div><div id="i3f14874d4dff44619437bc4e8219b905_16"></div><div style="margin-bottom:6pt;margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">QUARTERLY FINANCIAL HIGHLIGHTS (First-Quarter 2023 vs. First-Quarter 2022) </font></div><div style="margin-bottom:9pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">First-quarter 2023 revenues totaled $18.3 billion, a decrease of $7.4 billion, or 29%, compared to the prior-year quarter, reflecting an operational decline of $6.6 billion, or 26%, primarily due to a decrease in Comirnaty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> revenues globally, as well as an unfavorable impact of foreign exchange of $730 million, or 3%. First-quarter 2023 revenues from Comirnaty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> and Paxlovid were $7.1&#160;billion. Excluding contributions from Comirnaty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> and Paxlovid, company revenues grew $563 million, or 5%, operationally.</font></div><div style="margin-bottom:9pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Compared to the prior-year quarter, first-quarter 2023 revenue growth was unfavorably impacted by approximately 1% as a result of having one fewer selling day in international markets. This unfavorable impact is expected to reverse in the fourth quarter of 2023.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 5 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">First-quarter 2023 Comirnaty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> revenues declined $10&#160;billion, or 75%, operationally compared with the prior-year quarter, largely driven by lower contracted deliveries and demand in international markets, as well as lower U.S. government contracted deliveries with anticipated transition to traditional commercial market sales in the second half of 2023.</font></div><div style="margin-bottom:9pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">First-quarter Paxlovid revenues increased $2.8&#160;billion compared with the prior-year quarter, primarily driven by favorable timing of final delivery associated with the U.S. government contract before anticipated transition to traditional commercial markets in the second half of 2023&#59; strong demand in China due to increased COVID-19 infections&#59; and launch in certain international markets.</font></div><div style="margin-bottom:9pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Excluding contributions from Comirnaty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> and Paxlovid, first-quarter 2023 operational growth was primarily driven by&#58;</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:14.11pt">Recently acquired products, Nurtec ODT&#47;Vydura and Oxbryta, which contributed $167 million and $71 million in global revenues, respectively&#59;</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:14.11pt">Sulperazon internationally, up 64% operationally, largely driven by demand in China, which is not expected to be sustained&#59;</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:14.11pt">Eliquis globally, up 7% operationally, driven primarily by continued oral anti-coagulant adoption and market share gains in the non-valvular atrial fibrillation indication in the U.S. and certain markets in Europe, partially offset by declines due to loss of exclusivity and generic competition in certain international markets&#59; and</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:14.11pt">Vyndaqel family (Vyndaqel, Vyndamax, Vynmac) globally, up 16% operationally, largely driven by continued strong uptake of the transthyretin amyloid cardiomyopathy (ATTR-CM) indication, primarily in the U.S. and developed Europe, partially offset by a planned price decrease that went into effect in Japan in the second quarter of 2022,</font></div><div style="margin-bottom:9pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">partially offset primarily by lower revenues for&#58;</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:14.11pt">Xeljanz globally, down 33% operationally, driven primarily by lower net price in the U.S. due to unfavorable changes in channel mix, as well as decreased prescription volumes worldwide resulting from ongoing shifts in prescribing patterns related to label changes.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 6 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">GAAP Reported</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:700;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%"> Income Statement Highlights</font></div><div style="margin-bottom:6pt;margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">SELECTED REPORTED COSTS AND EXPENSES</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:700;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(2)</font></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.541%"><tr><td style="width:1.0%"></td><td style="width:38.010%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.719%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</font></td><td colspan="12" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First-Quarter</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</font></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</font></td><td colspan="6" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% Change</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oper.</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font></div></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;4,886&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;9,984&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51%)</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50%)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percent of Revenues</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N&#47;A</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N&#47;A</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SI&#38;A Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,418&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,593&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&#38;D Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,505&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,301&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&#38;D Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;21&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;355&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94%)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)&#47;Deductions&#8211;&#8211;net</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;70&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;350&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71%)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective Tax Rate on Reported Income</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">First-quarter 2023 Cost of Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> as a percentage of revenues decreased by 12.2 percentage points compared with the prior-year quarter, primarily driven by changes in sales mix, including lower sales of Comirnaty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> and higher sales of Paxlovid.</font></div><div style="margin-bottom:9pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">First-quarter 2023 SI&#38;A Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> increased 35% operationally compared with the prior-year quarter, primarily reflecting increased investments to support Paxlovid, recently acquired and launched products, and products across multiple customer groups.</font></div><div style="margin-bottom:9pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">First-quarter 2023 R&#38;D Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> increased 10% operationally compared with the prior-year quarter, primarily driven by increased investments to develop recently acquired assets and certain vaccine programs, as well as activities to support upcoming product launches, partially offset by lower spending on programs to prevent and treat COVID-19 and certain other late-stage clinical programs.</font></div><div style="margin-bottom:9pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">First-quarter 2023 acquired IPR&#38;D Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> decreased 94% operationally compared to the prior-year quarter, primarily driven by the non-recurrence of an upfront payment to Biohaven Pharmaceutical Holding Company Ltd. (Biohaven) and a premium paid on Pfizer&#8217;s equity investment in Biohaven, as well as a premium paid on Pfizer&#8217;s equity investment in BioNTech SE (BioNTech) to develop a potential mRNA vaccine against shingles &#8212; both recorded in the first quarter of 2022.</font></div><div style="margin-bottom:9pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Other deductions&#8211;&#8211;net</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> decreased 71% operationally in the first quarter of 2023 compared with the first quarter of 2022, primarily driven by lower net losses on equity securities, higher dividend income and lower net interest expense, partially offset by asset impairment charges in the first quarter of 2023, and lower net periodic benefit credits associated with pension and postretirement plans.</font></div><div style="margin-bottom:9pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Pfizer&#8217;s effective tax rate on Reported income</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> for the first quarter of 2023 decreased compared to the prior-year quarter primarily due to a favorable change in the jurisdictional mix of earnings.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 7 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Adjusted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:700;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%"> Income Statement Highlights</font></div><div style="margin-bottom:6pt;margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">SELECTED ADJUSTED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:700;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%"> COSTS AND EXPENSES</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.541%"><tr><td style="width:1.0%"></td><td style="width:38.010%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.719%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</font></td><td colspan="12" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First-Quarter</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</font></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</font></td><td colspan="6" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% Change</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oper.</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Cost of Sales</font></div></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;4,746&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;9,958&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</font></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percent of Revenues</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N&#47;A</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N&#47;A</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> SI&#38;A Expenses</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;3,350&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;2,496&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> R&#38;D Expenses</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;2,491&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;2,295&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Other (Income)&#47;Deductions&#8211;&#8211;net</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(528)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(406)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective Tax Rate on Adjusted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Income</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Reconciliations of certain Reported</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> to non-GAAP Adjusted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> financial measures and associated footnotes can be found in the financial tables section of this press release.</font></div><div id="i3f14874d4dff44619437bc4e8219b905_22"></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">RECENT NOTABLE DEVELOPMENTS (Since January&#160;31, 2023)</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Product Developments</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;padding-left:14.11pt">Braftovi (encorafenib) and Mektovi (binimetinib)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> &#8211; In April 2023, Pfizer announced the U.S. Food and Drug Administration (FDA) accepted for review the supplemental New Drug Applications (sNDAs) for Braftovi + Mektovi for patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. The Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA is in the fourth quarter of 2023 for the sNDAs.</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;padding-left:14.11pt">Cibinqo (abrocitinib)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> &#8211; In February 2023, Pfizer announced the FDA approved an sNDA for Cibinqo, expanding its indication to include adolescents (12 to &#60;18 years) with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable. Cibinqo was previously approved in the U.S. only for the treatment of adults 18 years and older.</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;padding-left:14.11pt">Comirnaty (COVID-19 vaccine, mRNA)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:700;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(8)</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:45pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;padding-left:18.61pt">Regulatory Developments</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:18.61pt">In April 2023, the FDA amended the emergency use authorization (EUA) of the Pfizer-BioNTech Omicron BA.4&#47;BA.5-adapted bivalent COVID-19 vaccine to simplify the vaccination schedule for most individuals. This action included authorizing the bivalent vaccine to be used for all doses administered to individuals six months of age and older, including for an additional dose or doses </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 8 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">for certain populations such as older adults and the immunocompromised. The monovalent Pfizer-BioNTech COVID-19 vaccine is no longer authorized for emergency use in the U.S.</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:19.28pt">In March 2023, Pfizer and BioNTech announced the FDA granted EUA to provide a single 3-&#181;g booster dose of the companies&#8217; Omicron BA.4&#47;BA.5-adapted bivalent COVID-19 vaccine in children six months through four years of age (also referred to as under five years of age) at least two months after completion of primary vaccination with three doses of the Pfizer-BioNTech COVID-19 Vaccine &#91;Original&#93;. Simultaneously, the FDA authorized the bivalent vaccine in this age group as the third dose of a three-dose primary series. The companies have submitted an application to the European Medicines Agency (EMA) to extend the Omicron BA.4&#47;BA.5-adapted bivalent vaccine&#8217;s marketing authorization (MA) to include use in children six months through four years of age as both primary series (all three doses) and booster vaccination (fourth dose).</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:18.61pt">In February 2023, Pfizer and BioNTech announced the submission of a supplemental Biologics License Application (sBLA) to the FDA for approval of the companies&#8217; Omicron BA.4&#47;BA.5-adapted bivalent COVID-19 vaccine (Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4&#47;BA.5)) as a primary series and booster dose(s) for individuals 12 years of age and older. The companies have also submitted an application to the EMA for a variation of the MA to include the bivalent vaccine as a primary course of vaccination in individuals five years of age and older. In the European Union, the bivalent vaccine was previously granted full MA for administration as a booster dose in individuals five years of age and older.</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;padding-left:14.11pt">Paxlovid (nirmatrelvir &#91;PF-07321332&#93; tablets and ritonavir tablets)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:700;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(8)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> &#8211; In March 2023, Pfizer announced the FDA&#8217;s Antimicrobial Drugs Advisory Committee (AMDAC) voted that available data support the safety and effectiveness of Paxlovid for the treatment of mild-to-moderate COVID-19 in adult patients who are at high risk for progression to severe illness. The AMDAC's vote, while not binding, will be considered by the FDA when making its decision regarding the potential approval of Paxlovid. If approved by the FDA, Paxlovid could be the first U.S. FDA-approved oral treatment for COVID-19. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">The target PDUFA action date for a decision by the FDA is in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">May 2023.</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;padding-left:14.11pt">Prevnar 20 (20-valent pneumococcal conjugate vaccine) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8211; In April 2023, Pfizer announced the FDA approved Prevnar 20 (20-valent Pneumococcal Conjugate Vaccine) for the prevention of invasive pneumococcal disease (IPD) caused by the 20 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:174%">Streptococcus pneumoniae</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> (pneumococcal) serotypes contained in the vaccine in infants and children six weeks through 17 years of age, and for the prevention of otitis media in infants six weeks through five years of age caused by the original seven serotypes contained in Prevnar. Prevnar 20 offers the broadest serotype coverage of any pediatric pneumococcal conjugate </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 9 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">vaccine, helping to protect against all 20 serotypes contained in the vaccine.</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;padding-left:14.11pt">Talzenna (talazoparib)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> &#8211; In February 2023, Pfizer announced positive results from the Phase 3 TALAPRO-2 study of Talzenna, an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide), demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared to placebo plus Xtandi in men with metastatic castration-resistant prostate cancer (mCRPC), with or without homologous recombination repair (HRR) gene mutations. Additionally, the FDA granted priority review for Pfizer&#8217;s sNDA for Talzenna in combination with Xtandi for the treatment of men with mCRPC. The FDA&#8217;s decision on the sNDA is </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">expected in 2023. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">In addition, the marketing authorization application (MAA) for this same indication has also been accepted for review by the EMA. </font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;padding-left:14.11pt">Xtandi (enzalutamide)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> &#8211; In April 2023, Astellas Pharma and Pfizer announced that Xtandi plus leuprolide significantly reduced the risk of metastasis or death by 58% versus placebo plus leuprolide, as assessed by the primary endpoint of metastasis-free survival (MFS), in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC&#59; also known as non-metastatic castration-sensitive prostate cancer or nmCSPC) with high-risk biochemical recurrence (BCR). These data from the Phase 3 EMBARK trial were presented as a plenary session during the 2023 American Urological Association Annual Meeting, and detailed results from the trial will be submitted for peer-reviewed publication. Additionally, the EMBARK data will be discussed with regulatory authorities, including the FDA, to support a potential regulatory submission for Xtandi in this indication in 2023.</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;padding-left:14.11pt">Zavzpret (zavegepant)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> &#8211; In March 2023, Pfizer announced the FDA approved Zavzpret, the first and only calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray for the acute treatment of migraine with or without aura in adults. In the pivotal Phase 3 study, published in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:174%">The Lancet Neurology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">, Zavzpret was statistically superior to placebo on the co-primary endpoints of pain freedom and freedom from most bothersome symptom at two hours post-dose. The pivotal study also demonstrated pain relief as early as 15 minutes in a prespecified secondary endpoint versus placebo. In clinical trials, Zavzpret was well tolerated. Zavzpret is anticipated to be available in pharmacies in July 2023.</font></div><div id="i3f14874d4dff44619437bc4e8219b905_25"></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Pipeline Developments</font></div><div style="margin-bottom:9pt;margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">A comprehensive update of Pfizer&#8217;s development pipeline was published today and is now available at www.pfizer.com&#47;science&#47;drug-product-pipeline. It includes an overview of Pfizer&#8217;s research and a list of compounds in development with targeted indication and phase of development, as well as mechanism of action for some candidates in Phase 1 and all candidates from Phase 2 through registration.</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;padding-left:14.11pt">Elranatamab (PF-06863135) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8211; In February 2023, Pfizer announced the FDA granted priority review for the company&#8217;s Biologics License Application (BLA) for elranatamab, an investigational B-cell maturation </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 10 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">antigen (BCMA) CD3-targeted bispecific antibody (BsAb), for the treatment of patients with relapsed or refractory multiple myeloma (RRMM). The FDA&#8217;s decision on the application is expected in 2023</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> The EMA also accepted elranatamab&#8217;s MAA.</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;padding-left:14.11pt">RSVpreF (Respiratory Syncytial Virus (RSV) Bivalent Vaccine Candidate) </font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:58.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:14.15pt">Pfizer today reports positive top-line results from the Phase 3 study evaluating the safety and immunogenicity of its RSV bivalent vaccine candidate, PF-06928316 or RSVpreF, coadministered with seasonal inactivated influenza vaccine (SIIV) in adults 65 years and older. The study met its primary endpoint, demonstrating non-inferiority for all four flu strains and both RSV groups. These results show that RSVpreF, if approved, can be administered concomitantly with SIIV. </font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:58.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:14.15pt">In February 2023, Pfizer announced the FDA accepted for priority review a BLA for its respiratory syncytial virus (RSV) vaccine candidate, PF-06928316 or RSVpreF, for the prevention of medically attended lower respiratory tract illness (MA-LRTI) and severe MA-LRTI caused by RSV in infants from birth up to six months of age by active immunization of pregnant individuals. If approved, RSVpreF would be the first vaccine for administration to pregnant individuals to help protect against the complications of RSV disease in infants from birth through six months. The PDUFA goal date for a decision by the FDA is in August 2023. Pfizer also announced that the EMA accepted Pfizer&#8217;s MAA under accelerated assessment for its RSV vaccine candidate for both older adults and maternal immunization to help protect infants. A decision is expected in the second half of 2023.</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:58.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:14.15pt">In February 2023, Pfizer announced that the FDA&#8217;s Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that available data are adequate to support the safety and effectiveness of its RSV bivalent vaccine candidate, PF-06928316 or RSVpreF. The vaccine candidate is currently under FDA review for the prevention of acute respiratory disease and lower respiratory tract disease caused by RSV in adults 60 years of age and older. The FDA&#8217;s decision in older adults is expected by the PDUFA goal date in May 2023.</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#9642;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;padding-left:14.11pt">Shingles (Varicella-zoster Virus, or VZV) mRNA Candidates</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> &#8211; In February 2023, Pfizer and BioNTech announced the start of a Phase 1&#47;2 trial exploring the safety, tolerability and immunogenicity of the companies&#8217; mRNA vaccine candidates against shingles (also known as herpes zoster, or HZ). The study is aiming to enroll up to 900 healthy volunteers 50 through 69 years of age and is being conducted in the U.S. Phase 1 will help select the optimal mRNA vaccine candidate, dose level, dosing schedule and formulation for advancement to Phase 2. Participants in the study will be followed to determine how long protection may last.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> </font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;padding-left:14.11pt">VLA15 (Lyme Disease Vaccine Candidate)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> &#8211; In February 2023, Pfizer and Valneva SE announced that Pfizer, as the study sponsor, decided to discontinue a significant percentage of participants in the U.S. who </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 11 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">had been enrolled in the Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524) Phase 3 clinical study. These study participants, representing approximately half of the total recruited participants in the trial, are being discontinued following violations of Good Clinical Practice (GCP) at certain clinical trial sites run by a third-party clinical trial site operator. The discontinuation of these participants was not due to any safety concerns with the investigational vaccine and was not prompted by a participant-reported adverse event. The clinical trial remains ongoing at other sites not operated by the third party, and Pfizer continues to enroll new participants at those sites.</font></div><div id="i3f14874d4dff44619437bc4e8219b905_28"></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Corporate Developments</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:14.11pt">In March 2023, Pfizer announced it entered into a definitive merger agreement under which Pfizer will acquire Seagen Inc., a global biotechnology company that discovers, develops and commercializes transformative cancer medicines, for $229 in cash per Seagen share for a total enterprise value of approximately $43 billion. Pfizer expects to finance the transaction substantially through $31 billion of new, long-term debt, and the balance from a combination of short-term financing and existing cash. The companies expect to complete the transaction in late 2023 or early 2024, subject to fulfillment of customary closing conditions, including approval of Seagen&#8217;s stockholders and receipt of required regulatory approvals. When combining the expected strong growth trajectories for Seagen&#8217;s in-line medicines with candidates that could emerge from Seagen&#8217;s pipeline, subject to clinical and regulatory success, Pfizer believes Seagen could contribute more than $10 billion in risk-adjusted revenues in 2030, with potential significant growth beyond 2030.</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:14.11pt">In March 2023, it was announced that the Alliance between Merck KGaA, Darmstadt, Germany, (Merck KGaA) and Pfizer to co-develop and co-commercialize Bavencio (avelumab) will terminate. Effective June 30, 2023, Merck KGaA will take full control of the global commercialization of Bavencio. The current profit share will be replaced by a 15% royalty to Pfizer on net sales of Bavencio. Merck KGaA and Pfizer will continue to operationalize their respective ongoing clinical trials for Bavencio&#59; and Merck KGaA will control all future research and development activities.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 12 -</font></div></div></div><div id="i3f14874d4dff44619437bc4e8219b905_31"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">For additional details, see the attached financial schedules, product revenue tables and disclosure notice.</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:31.5pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:14.18pt">As used in this document, &#8220;Comirnaty&#8221; refers to, as applicable, and as authorized or approved, the Pfizer-BioNTech COVID-19 Vaccine, the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4&#47;BA.5), the Comirnaty Original&#47;Omicron BA.1 Vaccine, and Comirnaty Original&#47;Omicron BA.4&#47;BA.5 Vaccine. In the U.S., monovalent mRNA COVID-19 vaccines are no longer emergency use authorized or CDC-recommended, although Comirnaty remains a licensed vaccine. &#8220;Comirnaty&#8221; includes direct sales and alliance revenues related to sales of the above-mentioned vaccines, which are recorded within Pfizer&#8217;s Primary Care customer group. It does not include revenues for certain Comirnaty-related manufacturing activities performed on behalf of BioNTech, which are included in the Pfizer CentreOne contract development and manufacturing organization. Revenues related to these manufacturing activities totaled $5 million for the first quarter of 2023 and $47 million for the first quarter of 2022.  </font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:31.5pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:14.18pt">Revenues is defined as revenues in accordance with U.S. generally accepted accounting principles (GAAP).&#160;Reported net income and its components are defined as net income attributable to Pfizer Inc. common shareholders and its components in accordance with U.S. GAAP. Reported diluted earnings per share (EPS) is defined as diluted EPS attributable to Pfizer Inc. common shareholders in accordance with U.S. GAAP.</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:31.5pt;text-indent:-27pt"><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:15.34pt">Adjusted income and Adjusted diluted EPS are defined as U.S. GAAP net income attributable to Pfizer Inc. common shareholders and Reported diluted EPS attributable to Pfizer Inc. common shareholders before the impact of amortization of intangible assets, certain acquisition-related items, discontinued operations and certain significant items. See the accompanying reconciliations of certain GAAP Reported to Non-GAAP Adjusted information for the first quarter of 2023 and 2022. Adjusted income and its components and Adjusted diluted EPS measures are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">. See the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:174%">Non-GAAP Financial Measure&#58; Adjusted Income</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> section of Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations in Pfizer&#8217;s 2022 Annual Report on Form 10-K and the accompanying </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:174%">Non-GAAP Financial Measure&#58; Adjusted Income</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> section of this press release for a definition of each component of Adjusted income as well as other relevant information.&#160;&#160;</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:31.5pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:14.18pt">Pfizer does not provide guidance for GAAP Reported financial measures (other than revenues and acquired in-process R&#38;D (IPR&#38;D) expenses) or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP Reported financial measures on a forward-looking basis because it is unable to predict with reasonable certainty the ultimate outcome of unusual gains and losses, certain acquisition-related expenses, gains and losses from equity securities, actuarial gains and losses from pension and postretirement plan remeasurements, potential future asset impairments and pending </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 13 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">litigation without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on GAAP Reported results for the guidance period.</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Financial guidance for full-year 2023 reflects the following&#58;</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:14.11pt">Does not assume the completion of any business development transactions&#160;not completed as of April&#160;2, 2023, except for signed transactions, if any, through mid-April 2023, which are expected to give rise to acquired IPR&#38;D expenses during fiscal 2023.</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:14.11pt">Reflects an anticipated negative revenue impact of $0.2&#160;billion due to recent and expected generic and biosimilar competition for certain products that have recently lost patent protection or that are anticipated to lose patent protection during fiscal-year 2023. </font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:14.11pt">Exchange rates assumed are a blend of actual rates in effect through the first quarter of 2023 and mid-April 2023 rates for the remainder of the year. Financial guidance reflects the anticipated unfavorable impact of approximately $0.4&#160;billion on revenues and approximately $0.13 on Adjusted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> diluted EPS as a result of changes in foreign exchange rates relative to the U.S. dollar compared to foreign exchange rates from 2022. </font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:14.11pt">Guidance for Adjusted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> diluted EPS assumes diluted weighted-average shares outstanding of approximately 5.75 billion shares, and assumes no share repurchases in 2023.</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:31.5pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:14.18pt">Pfizer&#8217;s fiscal year-end for international subsidiaries is November 30 while Pfizer&#8217;s fiscal year-end for U.S. subsidiaries is December 31. Therefore, Pfizer&#8217;s first quarter for U.S. subsidiaries reflects the three months ended on April&#160;2, 2023 and April&#160;3, 2022, while Pfizer&#8217;s first quarter for subsidiaries operating outside the U.S. reflects the three months ended on February&#160;26, 2023 and February&#160;27, 2022.</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:31.5pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:14.18pt">Beginning in the third quarter of 2022, Pfizer made several organizational changes to further transform its operations to better leverage its expertise in certain areas and in anticipation of potential future new product and indication launches. Biopharma, Pfizer&#8217;s innovative science-based biopharmaceutical business, is operating under a new commercial structure designed to better support and optimize performance across three broad customer groups&#58;</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:14.11pt">Primary Care, consisting of the former Internal Medicine and Vaccines product portfolios, products for COVID-19 prevention and treatment, and potential future mRNA and antiviral products.</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:14.11pt">Specialty Care, consisting of the former Inflammation &#38; Immunology, Rare Disease and Hospital (excluding Paxlovid) product portfolios.</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:14.11pt">Oncology, consisting of the former Oncology product portfolio.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 14 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:31.5pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(7)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:14.18pt">References to operational variances in this press release pertain to period-over-period changes that exclude the impact of foreign exchange rates. Although exchange rate changes are part of Pfizer&#8217;s business, they are not within Pfizer&#8217;s control, and because they can mask positive or negative trends in the business, Pfizer believes presenting operational variances excluding these foreign exchange changes provides useful information to evaluate Pfizer&#8217;s results.</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:31.5pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(8)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:14.18pt">Paxlovid and the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4&#47;BA.5) have not been approved or licensed by the FDA. Paxlovid has been authorized for emergency use by the FDA under an EUA, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with a current diagnosis of mild-to-moderate COVID-19 and who are at high risk for progression to severe COVID-19, including hospitalization or death. The Pfizer-BioNTech COVID-19 Vaccine, Bivalent has been authorized by the FDA under an EUA to prevent COVID-19 in individuals aged 6 months and older. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product during the COVID-19 pandemic under Section 564(b)(1) of the FFDCA unless the declaration is terminated or authorization revoked sooner. Please see the EUA Fact Sheets at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%;text-decoration:underline">www.covid19oralrx.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%;text-decoration:underline">www.cvdvaccine-us.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:-9pt"><font><br></font></div><div style="margin-bottom:7pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.619%"><tr><td style="width:1.0%"></td><td style="width:11.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.137%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.686%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.195%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contacts&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Media</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Investors</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PfizerMediaRelations&#64;Pfizer.com</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212.733.1226</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IR&#64;Pfizer.com</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212.733.4848</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 15 -</font></div></div></div><div id="i3f14874d4dff44619437bc4e8219b905_34"></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PFIZER INC. AND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> SUBSIDIARY COMPANIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF INCOME</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(UNAUDITED)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(millions, except per share data)</font></div></div><div><font><br></font></div><div id="i3f14874d4dff44619437bc4e8219b905_37"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.751%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.639%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">First-Quarter</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">% Incr. &#47;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2023</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(Decr.)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Revenues</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">18,282&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">25,661&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(29)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Costs and expenses&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cost of sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,886&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">9,984&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(51)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Selling, informational and administrative expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,418&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2,593&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">32</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Research and development expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,505&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2,301&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Acquired in-process research and development expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">21&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">355&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(94)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Amortization of intangible assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,103&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">835&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">32</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restructuring charges and certain acquisition-related costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">192&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(96)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other (income)&#47;deductions&#8211;&#8211;net</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(5)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">70&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">350&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(80)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Income from continuing operations before provision&#47;(benefit) for taxes on income</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6,270&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9,050&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(31)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Provision&#47;(benefit) for taxes on income</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">(6)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">715&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,172&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(39)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Income from continuing operations</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,555&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7,879&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(29)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Discontinued operations&#8211;&#8211;net of tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(9)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">*</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net income before allocation to noncontrolling interests</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,556&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7,870&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(29)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Less&#58; Net income attributable to noncontrolling interests</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">13&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">*</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net income attributable to Pfizer Inc. common shareholders</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">5,543&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">7,864&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(30)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Earnings per common share&#8211;&#8211;basic&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Income from continuing operations attributable to Pfizer Inc. common shareholders</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">0.98&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">1.40&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(30)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Discontinued operations&#8211;&#8211;net of tax</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">*</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net income attributable to Pfizer Inc. common shareholders</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">0.98&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">1.40&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(30)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Earnings per common share&#8211;&#8211;diluted&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Income from continuing operations attributable to Pfizer Inc. common shareholders</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">0.97&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">1.37&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(29)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Discontinued operations&#8211;&#8211;net of tax</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">*</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net income attributable to Pfizer Inc. common shareholders</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">0.97&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">1.37&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(29)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Weighted-average shares used to calculate earnings per common share&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Basic</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,634&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">5,617&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Diluted</font></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,727&#160;</font></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">5,758&#160;</font></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:4.25pt">Indicates calculation not meaningful.</font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 16 -</font></div></div></div><div id="i3f14874d4dff44619437bc4e8219b905_40"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">NOTES TO CONSOLIDATED STATEMENTS OF INCOME - (UNAUDITED)</font></div></div><div style="margin-bottom:3pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">The financial statements present the three months ended April&#160;2, 2023 and April&#160;3, 2022. Subsidiaries operating outside the U.S. are included for the three months ended February&#160;26, 2023 and February&#160;27, 2022.</font></div><div style="margin-bottom:3pt;padding-left:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial results for the three months ended April&#160;2, 2023 are not necessarily indicative of the results that ultimately could be achieved for the full year.</font></div><div style="margin-bottom:3pt;padding-left:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business development activities impacted financial results in the periods presented. See </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes 1A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the consolidated financial statements in Pfizer&#8217;s 2022 Annual Report on Form 10-K. Discontinued operations in the periods presented relate to post-close adjustments.</font></div><div style="margin-bottom:5pt;padding-left:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts in the consolidated statements of income and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.</font></div><div style="margin-bottom:5pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Exclusive of amortization of intangible assets.</font></div><div style="margin-bottom:5pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:15.34pt">Acquired in-process research and development expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> includes costs incurred in connection with (a) all upfront and milestone payments on collaboration and in-license agreements, including premiums on equity securities and (b) asset acquisitions of acquired in-process research and development.</font></div><div style="padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:15.34pt">Restructuring charges and certain acquisition-related costs </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">include the following&#58;</font></div><div style="padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.642%"><tr><td style="width:1.0%"></td><td style="width:75.315%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.750%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First-Quarter</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges&#47;(credits)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8211;&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">acquisition-related costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges&#47;(credits)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8211;&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">cost reduction initiatives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges&#47;(credits)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integration costs and other</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Restructuring charges and certain acquisition-related costs</font></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt">Includes charges&#47;(credits) for employee terminations, asset impairments and other exit costs associated with business combinations.</font></div><div style="padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:10.43pt">Includes charges&#47;(credits) for employee terminations, asset impairments and other exit costs not associated with acquisitions. </font></div><div style="padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt">Transaction costs represent external costs for banking, legal, accounting and other similar services.</font></div><div style="margin-bottom:5pt;padding-left:45pt;text-indent:-18pt"><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Integration costs and other represent external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs.</font></div><div style="padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Components of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income)&#47;deductions&#8211;&#8211;net </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">include&#58;</font></div><div style="padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.642%"><tr><td style="width:1.0%"></td><td style="width:75.629%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.750%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First-Quarter</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(MILLIONS)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(177)</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net interest expense</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty-related income</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net (gains)&#47;losses on asset disposals</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net (gains)&#47;losses recognized during the period on equity securities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income from collaborations, out-licensing arrangements and sales of compound&#47;product rights</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit costs&#47;(credits) other than service costs</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(283)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain legal matters, net</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain asset impairments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Haleon&#47;Consumer Healthcare JV equity method (income)&#47;loss</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(184)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other, net</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(396)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income)&#47;deductions&#8211;&#8211;net</font></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt">The first quarter of 2023 primarily includes certain product liability expenses related to products discontinued and&#47;or divested by Pfizer. The first quarter of 2022 includes certain product liability expenses related to products discontinued and&#47;or divested by Pfizer, and to a lesser extent, legal obligations related to pre-acquisition commitments.</font></div><div style="padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The first quarter of 2023 primarily represents intangible asset impairment charges, including $128 million related to in-process research and development (IPR&#38;D) and developed technology rights for acquired software assets, </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 17 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">NOTES TO CONSOLIDATED STATEMENTS OF INCOME - (UNAUDITED)</font></div></div><div style="padding-left:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $120 million resulting from the discontinuation of a study related to an out-licensed IPR&#38;D asset for the treatment of prostate cancer.</font></div><div style="margin-bottom:5pt;padding-left:45pt;text-indent:-18pt"><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt">The first quarter of 2023 primarily includes, among other things, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dividend income of $211&#160;million related to our investment in Nimbus Therapeutics, LLC (Nimbus) resulting from Takeda Pharmaceutical Company Limited&#8217;s acquisition of Nimbus&#8217;s oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor program subsidiary, and $92&#160;million from our investment in ViiV Healthcare Limited.</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Our effective tax rates for income from continuing operations were 11.4% in the first quarter of 2023 and 12.9% in the first quarter of 2022. The decrease in the effective tax rate for the first quarter of 2023, compared to the first quarter of 2022, was due to a favorable change in the jurisdictional mix of earnings.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 18 -</font></div></div></div><div id="i3f14874d4dff44619437bc4e8219b905_46"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">NON-GAAP FINANCIAL MEASURE&#58; ADJUSTED INCOME</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted income is an alternative measure of performance used by management to evaluate our overall performance as a supplement to our GAAP Reported performance measures. As such, we believe that investors&#8217; understanding of our performance is enhanced by disclosing this measure. We use Adjusted income, certain components of Adjusted income and Adjusted diluted EPS to present the results of our major operations&#8211;&#8211;the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide&#8211;&#8211;prior to considering certain income statement elements as follows&#58;</font></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.879%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Measure</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Definition</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Relevance of Metrics to Our Business Performance</font></td></tr><tr style="height:71pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Adjusted income</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Net income attributable to Pfizer Inc. common shareholders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">before the impact of amortization of intangible assets, certain acquisition-related items, discontinued operations and certain significant items</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.85pt">Provides investors useful information to&#58;</font></div><div style="padding-left:18pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.81pt">evaluate the normal recurring operational activities, and their components, on a comparable year-over-year basis</font></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.81pt">assist in modeling expected future performance on a normalized basis</font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.85pt">Provides investors insight into the way we manage our budgeting and forecasting, how we evaluate and manage our recurring operations and how we reward and compensate our senior management</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</font></div></td></tr><tr style="height:71pt"><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Adjusted cost of sales, Adjusted selling, informational and administrative expenses, Adjusted research and development expenses and Adjusted other (income)&#47;deductions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">&#8211;&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">net</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Cost of sales, Selling, informational and administrative expenses, Research and development expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"> Other (income)&#47;deductions&#8211;&#8211;net</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"> (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">, each before the impact of amortization of intangible assets, certain acquisition-related items, discontinued operations and certain significant items, which are components of the Adjusted income measure</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:71pt"><td colspan="3" style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Adjusted diluted EPS</font></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">EPS attributable to Pfizer Inc. common shareholders&#8211;&#8211;diluted </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> before the impact of amortization of intangible assets, certain acquisition-related items, discontinued operations and certain significant items</font></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Most directly comparable GAAP measure.</font></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Beginning in the first quarter of 2022, we no longer exclude any expenses for acquired IPR&#38;D from our non-GAAP Adjusted results but we continue to exclude certain of these expenses for our financial results for annual incentive compensation purposes. </font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted income and its components and Adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by GAAP and, therefore, are limited in their usefulness to investors. Because of their non-standardized definitions, they may not be comparable to the calculation of similar measures of other companies and are presented to permit investors to more fully understand how management assesses performance. A limitation of these measures is that they provide a view of our operations without including all events during a period, and do not provide a comparable view of our performance to peers. These measures are not, and should not be viewed as, substitutes for their most directly comparable GAAP measures of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Net income attributable to Pfizer Inc. common shareholders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, components of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to Pfizer Inc. common shareholders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">EPS attributable to Pfizer Inc. common shareholders&#8212;diluted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also recognize that, as internal measures of performance, these measures have limitations, and we do not restrict our performance-management process solely to these measures. We also use other tools designed to achieve the highest levels of performance. For example, our R&#38;D organization has productivity targets, upon which its effectiveness is measured. In addition, total shareholder return, both on an absolute basis and relative to a publicly traded pharmaceutical index, plays a significant role in determining payouts under certain of our incentive compensation plans.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the reconciliations of certain GAAP Reported to Non-GAAP Adjusted information for the first quarters of 2023 and 2022 below and the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-GAAP Financial Measure&#58; Adjusted Income</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section of Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations in Pfizer&#8217;s 2022 Annual Report on Form 10-K for additional information.</font></div><div style="margin-bottom:3pt"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 19 -</font></div></div></div><div id="i3f14874d4dff44619437bc4e8219b905_49"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">RECONCILIATIONS OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">CERTAIN LINE ITEMS - (UNAUDITED)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(millions, except per share data)</font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.583%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.357%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.639%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.357%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.033%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.357%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.802%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.357%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.823%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.357%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.830%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="30" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">First-Quarter 2023</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Data presented will not (in all cases) aggregate to totals.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cost of sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Selling, informational and administrative expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income)&#47;deductions&#8211;&#8211;net</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net income attributable to Pfizer Inc. common shareholders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1), (2)</font></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Earnings per common share attributable to Pfizer Inc. common shareholders&#8211;&#8211;diluted</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">GAAP Reported</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,886</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,418</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">70</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5,543</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">0.97</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-right:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortization of intangible assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,103&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquisition-related items</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(97)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">163&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Discontinued operations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain significant items&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Restructuring charges&#47;(credits) and implementation costs and additional depreciation&#8212;asset restructuring</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(32)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(59)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain asset impairments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(264)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">264&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Gains)&#47;losses on equity securities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(452)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">452&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Actuarial valuation and other pension and postretirement plan (gains)&#47;losses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(8)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(10)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">107&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(88)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Income tax provision&#8212;non-GAAP items</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(437)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-GAAP Adjusted</font></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</font></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,746&#160;</font></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</font></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,350&#160;</font></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</font></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(528)</font></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(7)</font></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</font></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,036&#160;</font></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</font></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.23&#160;</font></td><td style="border-bottom:3pt double #000;border-right:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.444%"><tr><td style="width:1.0%"></td><td style="width:31.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.050%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.838%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.410%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="36" style="padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.027%"><tr><td style="width:1.0%"></td><td style="width:31.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.138%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.857%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.903%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.907%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.911%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="30" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">First-Quarter 2022</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Data presented will not (in all cases) aggregate to totals.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cost of sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Selling, informational and administrative expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income)&#47;deductions&#8211;&#8211;net</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net income attributable to Pfizer Inc. common shareholders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1), (2)</font></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Earnings per common share attributable to Pfizer Inc. common shareholders&#8211;&#8211;diluted</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">GAAP Reported</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">9,984</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,593</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">350</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,864</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1.37</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-right:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortization of intangible assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">835&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquisition-related items</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(26)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">187&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Discontinued operations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain significant items&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Restructuring charges&#47;(credits) and implementation costs and additional depreciation&#8212;asset restructuring</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(20)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(74)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">122&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Gains)&#47;losses on equity securities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(698)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">698&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Actuarial valuation and other pension and postretirement plan (gains)&#47;losses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">72&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(72)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(10)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(23)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(104)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">143&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Income tax provision&#8212;non-GAAP items</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(448)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-GAAP Adjusted</font></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</font></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9,958&#160;</font></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</font></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,496&#160;</font></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</font></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(406)</font></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(7)</font></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</font></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9,338&#160;</font></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</font></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.62&#160;</font></td><td style="border-bottom:3pt double #000;border-right:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.444%"><tr><td style="width:1.0%"></td><td style="width:31.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.050%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.838%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.410%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="36" style="padding:0 1pt 0 5.5pt;text-indent:-4.5pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 20 -</font></div></div></div><div id="i3f14874d4dff44619437bc4e8219b905_52"></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">NOTES TO RECONCILIATIONS OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">CERTAIN LINE ITEMS - (UNAUDITED)</font></div></div><div style="margin-bottom:5pt;padding-left:27pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Items that reconcile GAAP Reported to non-GAAP Adjusted balances are shown pre-tax. Our effective tax rates for GAAP Reported income from continuing operations were 11.4% in the first quarter of 2023 and 12.9% in the first quarter of 2022. See Note (6) to the Consolidated Statements of Income above. Our effective tax rates for non-GAAP Adjusted income were 14.0% in the first quarter of 2023 and 14.8% in the first quarter of 2022.</font></div><div style="margin-bottom:5pt;padding-left:27pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">The amounts for the first quarters of 2023 and 2022 include reconciling amounts for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that are not material.</font></div><div style="margin-bottom:5pt;padding-left:27pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">The amounts for the first quarters of 2023 and 2022 relate to post-close adjustments.</font></div><div style="margin-bottom:5pt;padding-left:27pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Includes employee termination costs, asset impairments and other exit costs related to our cost-reduction and productivity initiatives not associated with acquisitions.</font></div><div style="margin-bottom:5pt;padding-left:27pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">See Note (5) to the Consolidated Statements of Income above.</font></div><div style="margin-bottom:5pt;padding-left:27pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">For the first quarter of 2023, the total </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income)&#47;deductions&#8211;&#8211;net </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adjustment of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$107&#160;million primarily includes dividend income of $211&#160;million related to our investment in Nimbus Therapeutics, LLC (Nimbus) resulting from Takeda Pharmaceutical Company Limited&#8217;s acquisition of Nimbus&#8217;s oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor program subsidiary, partially offset by charges of (i) $50&#160;million mostly related to our equity-method accounting pro-rata share of intangible asset amortization and impairments, costs of separating from GSK plc and restructuring costs recorded by Haleon plc, and (ii) $36&#160;million for certain legal matters, primarily for certain product liability expenses related to products discontinued and&#47;or divested by Pfizer. For the first quarter of 2022, the total </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income)&#47;deductions&#8211;&#8211;net </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adjustment of $104&#160;million primarily included charges of $79&#160;million for certain legal matters representing certain product liability expenses related to products discontinued and&#47;or divested by Pfizer, and to a lesser extent, legal obligations related to pre-acquisition commitments.</font></div><div style="padding-left:27pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">The components of non-GAAP Adjusted </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income)&#47;deductions&#8211;&#8211;net</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> include the following&#58;</font></div><div style="margin-bottom:5pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.047%"><tr><td style="width:1.0%"></td><td style="width:74.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.591%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.134%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.591%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.135%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First-Quarter</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(MILLIONS</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(177)</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net interest expense</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty-related income</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net (gains)&#47;losses on asset disposals</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net (gains)&#47;losses recognized during the period on equity securities</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income from collaborations, out-licensing arrangements and sales of compound&#47;product rights</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit costs&#47;(credits) other than service costs</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Haleon&#47;Consumer Healthcare JV equity method (income)&#47;loss</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(190)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other, net</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP Adjusted </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income)&#47;deductions&#8211;&#8211;net</font></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(528)</font></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(406)</font></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;padding-left:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note (5) to the Consolidated Statements of Income above for additional information on the components comprising GAAP Reported </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income)&#47;deductions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">net</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 21 -</font></div></div></div><div id="i3f14874d4dff44619437bc4e8219b905_61"></div><hr style="page-break-after:always"><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">PFIZER INC. - REVENUES </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">FIRST-QUARTER 2023 and 2022 - (UNAUDITED) </font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.346%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="12" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">WORLDWIDE</font></td><td colspan="9" style="border-left:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">UNITED STATES</font></td><td colspan="12" style="border-bottom:0.5pt solid #000000;border-left:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">TOTAL INTERNATIONAL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</font></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2023</font></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2022</font></td><td colspan="6" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">% Change</font></td><td colspan="3" rowspan="2" style="border-left:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2023</font></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2022</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">% Change</font></td><td colspan="3" rowspan="2" style="border-left:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2023</font></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2022</font></td><td colspan="6" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">% Change</font></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(MILLIONS)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total</font></td><td colspan="3" style="border-right:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Oper.</font></td><td colspan="3" style="border-right:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Oper.</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">TOTAL REVENUES</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">18,282</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">25,661</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(29%)</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(26%)</font></td><td style="border-left:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">8,507</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">8,918</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(5%)</font></td><td style="border-left:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">9,775</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">16,743</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(42%)</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(37%)</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</font></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">17,971</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">25,323</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(29%)</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(26%)</font></td><td style="border-left:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">8,396</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">8,816</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(5%)</font></td><td style="border-left:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">9,575</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">16,507</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(42%)</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(38%)</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Primary Care</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">11,505</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">18,851</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(39%)</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(37%)</font></td><td style="border-left:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">5,087</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">5,694</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(11%)</font></td><td style="border-left:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">6,418</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">13,157</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(51%)</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(48%)</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Paxlovid</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">4,069&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,470&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</font></td><td colspan="2" style="border-left:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,960&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,015&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">93%</font></td><td colspan="2" style="border-left:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2,109&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">455&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:8pt;padding-left:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Comirnaty direct sales and alliance revenues</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3,064&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">13,227&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(77%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(75%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">328&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2,314&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(86%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2,735&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">10,913&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(75%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(73%)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Eliquis alliance revenues and direct sales</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,874&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,793&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">7%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,261&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,080&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">17%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">613&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">713&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(14%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(8%)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Prevnar family</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,593&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,565&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">4%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,075&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,014&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">518&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">551&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(6%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Nurtec ODT&#47;Vydura</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">167&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">163&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Premarin family</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">112&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">102&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">10%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">11%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">104&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">94&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">11%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">10%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">BMP2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">67&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">29%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">29%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">67&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FSME-IMMUN&#47;TicoVac</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">45&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">42&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">11%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">45&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">42&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">12%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Nimenrix</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">40&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">77&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(48%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(44%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">40&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">77&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(48%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(44%)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">All other Primary Care</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">456&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">507&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(10%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(4%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">109&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">110&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">347&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">397&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(13%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(5%)</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Specialty Care</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">3,612</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">3,505</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">3%</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">8%</font></td><td style="border-left:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,469</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,276</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">15%</font></td><td style="border-left:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2,143</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2,229</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(4%)</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">4%</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Vyndaqel family</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</font></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">686&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">612&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">12%</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">16%</font></td><td colspan="2" style="border-left:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">384&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">265&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">45%</font></td><td colspan="2" style="border-left:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">302&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">347&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(13%)</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(7%)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Sulperazon</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">320&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">210&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">320&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">210&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Xeljanz</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">237&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">372&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(36%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(33%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">90&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">203&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(55%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">147&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">169&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(13%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(6%)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Enbrel (Outside the U.S. and Canada)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">199&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">280&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(29%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(22%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">199&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">280&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(29%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(22%)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Inflectra</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">178&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">135&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">32%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">35%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">119&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">79&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">52%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">59&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">56&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">11%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Zithromax</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">150&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">125&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(39%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">149&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">124&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Genotropin</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">147&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">80&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">85%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">96%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">67&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">80&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">72&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">10%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">22%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Ig Portfolio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(f)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">126&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">107&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">126&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">107&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Zavicefta</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">116&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">104&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">116&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">104&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">BeneFIX</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">109&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">112&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(2%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">59&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">61&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(4%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">50&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">50&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">11%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Medrol</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">93&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Oxbryta</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Somavert</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">66&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">68&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(3%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">28&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">28&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">38&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">40&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(6%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Refacto AF&#47;Xyntha</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">60&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">66&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(9%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(2%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">16&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">18&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(12%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">44&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">48&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(7%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Fragmin</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">70&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(17%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(38%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">69&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(16%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10%)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Vfend</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(21%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(14%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(15%)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">All other Anti-infectives</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">374&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">381&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">118&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">108&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">256&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">273&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">All other Specialty Care</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">569&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">643&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">346&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">371&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">223&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">271&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(18%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12%)</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Oncology</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2,855</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2,967</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(4%)</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(1%)</font></td><td style="border-left:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,841</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,847</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#8212;</font></td><td style="border-left:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,014</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,120</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(10%)</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(2%)</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Ibrance</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,144&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,237&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(8%)</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(5%)</font></td><td colspan="2" style="border-left:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">750&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">753&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="2" style="border-left:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">394&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">484&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(19%)</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(12%)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Inlyta</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">259&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">234&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">11%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">14%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">155&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">140&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">11%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">104&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">94&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">11%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">18%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Xtandi alliance revenues</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">258&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">268&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(4%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(4%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">258&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">268&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(4%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Bosulif</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">150&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">128&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">17%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">21%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">105&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">82&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">29%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">44&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">46&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(3%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Zirabev</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">129&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">147&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(12%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(11%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">98&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">106&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(8%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">32&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">41&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(23%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(17%)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Ruxience</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">114&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">124&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">94&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">113&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(17%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">91%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Lorbrena</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">112&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">56%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">63%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">32%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">61&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">33&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">84%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">99%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Xalkori</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">111&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">127&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(13%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(8%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">27&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">24&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">13%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">83&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">103&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(19%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(13%)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Retacrit</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">93&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">115&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(19%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(18%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">72&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">95&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(24%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">21&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">12%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Bavencio alliance revenues</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">85&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">67&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">33%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">27%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">54&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">26%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">37%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Aromasin</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">77&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">34%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">56%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">76&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">24%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">34%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Besponsa</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">19%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">22%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">23&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">14%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Sutent</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">114&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(57%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(53%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(27%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">42&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">104&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(60%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(56%)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Braftovi</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">47&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">47&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Mektovi</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(3%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Trazimera</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(35%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(32%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(69%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">24&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">14%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">23%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">All other Oncology</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">92&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">81&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">38%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">38&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(15%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(9%)</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">BUSINESS INNOVATION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</font></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">310</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">338</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(8%)</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(5%)</font></td><td style="border-left:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">110</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">102</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">8%</font></td><td style="border-left:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">200</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">236</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(15%)</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(11%)</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Pfizer CentreOne</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(g)</font></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">306&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">338&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(10%)</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(7%)</font></td><td colspan="2" style="border-left:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">106&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">102&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">4%</font></td><td colspan="2" style="border-left:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">200&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">236&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(15%)</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(11%)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Pfizer Ignite</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="border-bottom:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-bottom:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</font></td><td colspan="2" style="border-bottom:0.5pt solid #000000;border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="border-bottom:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-bottom:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</font></td><td colspan="2" style="border-bottom:0.5pt solid #000000;border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-bottom:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-bottom:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td></tr><tr style="height:3pt"><td colspan="39" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total Alliance revenues included above</font></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2,060</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2,314</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(11%)</font></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(9%)</font></td><td style="border-bottom:0.5pt solid #000;border-left:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,580</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,387</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">14%</font></td><td style="border-bottom:0.5pt solid #000;border-left:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">480</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">927</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(48%)</font></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(44%)</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">See end of tables for notes.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 22 -</font></div></div></div><div id="i3f14874d4dff44619437bc4e8219b905_64"></div><hr style="page-break-after:always"><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">PFIZER INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">INTERNATIONAL REVENUES BY GEOGRAPHIC REGION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">FIRST-QUARTER 2023 and 2022 - (UNAUDITED)</font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.790%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.346%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="12" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">DEVELOPED EUROPE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(h)</font></div></td><td colspan="12" style="border-bottom:0.5pt solid #000000;border-left:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">DEVELOPED REST OF WORLD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(i)</font></div></td><td colspan="12" style="border-bottom:0.5pt solid #000000;border-left:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">EMERGING MARKETS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(j)</font></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2023</font></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2022</font></td><td colspan="6" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">% Change</font></td><td colspan="3" rowspan="2" style="border-left:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2023</font></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2022</font></td><td colspan="6" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">% Change</font></td><td colspan="3" rowspan="2" style="border-left:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2023</font></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2022</font></td><td colspan="6" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">% Change</font></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(MILLIONS)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total</font></td><td colspan="3" style="border-right:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Oper.</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total</font></td><td colspan="3" style="border-right:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Oper.</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Oper.</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">TOTAL INTERNATIONAL REVENUES</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2,822</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">6,090</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(54%)</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(51%)</font></td><td style="border-left:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2,473</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">3,286</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(25%)</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(17%)</font></td><td style="border-left:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">4,480</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">7,367</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(39%)</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(36%)</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</font></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2,664</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">5,905</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(55%)</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(52%)</font></td><td style="border-left:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2,451</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">3,267</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(25%)</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(17%)</font></td><td style="border-left:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">4,460</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">7,335</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(39%)</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(35%)</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Primary Care</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,625</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">4,736</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(66%)</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(63%)</font></td><td style="border-left:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,891</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2,541</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(26%)</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(18%)</font></td><td style="border-left:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2,903</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">5,880</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(51%)</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(48%)</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Paxlovid</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">367&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">216&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">70%</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">82%</font></td><td colspan="2" style="border-left:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">539&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">183&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</font></td><td colspan="2" style="border-left:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,202&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">56&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:8pt;padding-left:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Comirnaty direct sales and alliance revenues</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">596&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3,808&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(84%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(83%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,124&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2,067&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(46%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(39%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,015&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5,038&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(80%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(80%)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Eliquis alliance revenues and direct sales</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">339&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">375&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(10%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(4%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">72&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">113&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(36%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(28%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">201&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">224&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(10%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(6%)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Prevnar family</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">142&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">132&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">7%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">15%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">84&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">89&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(5%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">291&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">330&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(12%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(7%)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Nurtec ODT&#47;Vydura</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Premarin family</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(22%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(15%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">45%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">52%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">BMP2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FSME-IMMUN&#47;TicoVac</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">39&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">37&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">4%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">10%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">17%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">23%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Nimenrix</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">20&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">24&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(19%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(13%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(5%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">15&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">47&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(68%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(65%)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">All other Primary Care</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">122&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">144&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(15%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(10%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">61&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">79&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(24%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(15%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">164&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">175&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(6%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">4%</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Specialty Care</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">659</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">687</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(4%)</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2%</font></td><td style="border-left:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">359</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">498</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(28%)</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(21%)</font></td><td style="border-left:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,125</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,045</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">8%</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">17%</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Vyndaqel family</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</font></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">227&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">189&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">20%</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">27%</font></td><td colspan="2" style="border-left:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">55&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">143&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(62%)</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(56%)</font></td><td colspan="2" style="border-left:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">20&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">15&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">29%</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">40%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Sulperazon</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(75%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(71%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">320&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">209&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">53%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">65%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Xeljanz</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">52&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">61&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(14%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(9%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">47&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">61&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(23%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(14%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">48&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">47&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">9%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Enbrel (Outside the U.S. and Canada)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">78&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">113&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(30%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(26%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">35&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">60&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(42%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(35%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">86&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">107&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(20%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(12%)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Inflectra</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">26&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">32&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(18%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(13%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">30&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">21&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">40%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">48%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">9%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">14%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Zithromax</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">21&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(11%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">124&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">110&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">13%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">23%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Genotropin</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">27&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">27&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">7%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">24&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">24&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">11%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">29&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">22&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">33%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">52%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Ig Portfolio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(f)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Zavicefta</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">27&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">28&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(5%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">89&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">76&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">17%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">29%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">BeneFIX</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">11&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">15&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(24%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(19%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">13&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">14&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(6%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">26&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">22&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">20%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">38%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Medrol</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">15&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">14&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">12%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(8%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">28&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">26&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">11%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Oxbryta</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Somavert</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">28&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">31&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(10%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(5%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(9%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">31%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">45%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Refacto AF&#47;Xyntha</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">17&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">22&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(24%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(19%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(16%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(11%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">24&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">21&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">12%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">28%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Fragmin</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">35&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">37&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(6%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">10&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">12&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(18%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(13%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">13&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">20&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(35%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(31%)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Vfend</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(30%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(25%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">10&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">11&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(13%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(2%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">37&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">49&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(24%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(18%)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">All other Anti-infectives</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">66&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">72&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(9%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(3%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">23&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">27&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(14%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(5%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">167&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">174&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(4%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">4%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">All other Specialty Care</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">25&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">32&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(21%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(15%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">91&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(9%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(2%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">107&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">140&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(23%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(18%)</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Oncology</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">380</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">482</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(21%)</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(16%)</font></td><td style="border-left:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">201</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">228</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(12%)</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(1%)</font></td><td style="border-left:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">432</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">410</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">5%</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">13%</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Ibrance</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">174&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">238&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(27%)</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(22%)</font></td><td colspan="2" style="border-left:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">85&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">106&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(20%)</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(9%)</font></td><td colspan="2" style="border-left:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">135&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">141&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(4%)</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Inlyta</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">38&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">35&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">7%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">14%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">16&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">19&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(20%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(10%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">51&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">39&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">29%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">35%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Xtandi alliance revenues</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Bosulif</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">23&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">23&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(2%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">4%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">15&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">17&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(11%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">9%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">23%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Zirabev</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">20&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">28&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(28%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(23%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">10&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(16%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(6%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(7%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Ruxience</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">72%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">82%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">16%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Lorbrena</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">18&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">16&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">11%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">18%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">11&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">13%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">26%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">32&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Xalkori</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">18&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">22&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(19%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(14%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">10&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(18%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(8%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">57&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">70&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(19%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(13%)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Retacrit</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">20&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">19&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">9%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Bavencio alliance revenues</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">25&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">21&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">21%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">28%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">20&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">17&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">16%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">32%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">77%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">87%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Aromasin</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(4%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(29%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(20%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">69&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">54&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">29%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">39%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Besponsa</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(8%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(2%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(25%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(16%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">94%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Sutent</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">31&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(84%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(83%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">11&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">14&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(21%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(13%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">26&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">59&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(56%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(51%)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Braftovi</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Mektovi</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Trazimera</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">10&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(8%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(3%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">13%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">13&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">10&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">38%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">49%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">All other Oncology</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">11&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">21&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(48%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(45%)</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">27%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">35%</font></td><td colspan="2" style="border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">13&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">11&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">22%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">34%</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">BUSINESS INNOVATION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</font></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">157</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">185</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(15%)</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(11%)</font></td><td style="border-left:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">19%</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">34%</font></td><td style="border-left:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">33</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(39%)</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(40%)</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Pfizer CentreOne</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(g)</font></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">157&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">185&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(15%)</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(11%)</font></td><td colspan="2" style="border-left:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">23&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">19&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">19%</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">34%</font></td><td colspan="2" style="border-left:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">20&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">33&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(39%)</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(40%)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Pfizer Ignite</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="border-bottom:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="border-bottom:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="2" style="border-bottom:0.5pt solid #000000;border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="border-bottom:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="border-bottom:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="2" style="border-bottom:0.5pt solid #000000;border-left:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="border-bottom:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="border-bottom:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td></tr><tr style="height:3pt"><td colspan="42" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total Alliance revenues included above</font></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">376</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">771</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(51%)</font></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(48%)</font></td><td style="border-bottom:0.5pt solid #000;border-left:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">96</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">136</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(30%)</font></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(21%)</font></td><td style="border-bottom:0.5pt solid #000;border-left:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</font></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(56%)</font></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(44%)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 23 -</font></div></div></div><div id="i3f14874d4dff44619437bc4e8219b905_73"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;margin-top:6pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">PFIZER INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NOTES TO REVENUES TABLE INFORMATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(UNAUDITED)</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.452%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(a)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Total International represents Developed Europe region + Developed Rest of World region + Emerging Markets region. Details for these regions are described in footnotes (h) to (j) below, respectively.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(b)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">We manage our commercial operations through two operating segments, each led by a single manager&#58; Biopharma, our innovative science-based biopharmaceutical business, and Business Innovation, an operating segment established in the first quarter of 2023 that includes Pfizer CentreOne (PC1), the company&#8217;s global contract development and manufacturing organization and a leading supplier of specialty active pharmaceutical ingredients, and Pfizer Ignite, a recently launched offering of strategic guidance and end-to-end R&#38;D services to select innovative biotech companies that align with Pfizer&#8217;s R&#38;D focus areas. Beginning in the third quarter of 2022, we made several organizational changes to further transform our operations to better leverage our expertise in certain areas and in anticipation of potential future new product and indication launches. These changes included establishing a new commercial structure within Biopharma focused on three broad customer groups (primary care, specialty care and oncology). Prior-period financial information has been revised to reflect the current period presentation.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(c)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Excludes revenues for certain Comirnaty-related manufacturing activities performed on behalf of BioNTech, which are included in the PC1 contract development and manufacturing organization. See footnote (g) below.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(d)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Prevnar family includes revenues from Prevnar 13&#47;Prevenar 13 (pediatric and adult) and Prevnar 20&#47;Apexxnar (adult).</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(e)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Vyndaqel family includes global revenues from Vyndaqel, as well as revenues for Vyndamax in the U.S. and Vynmac in Japan.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(f)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Immunoglobulin (Ig) portfolio includes the revenues from Panzyga, Octagam and Cutaquig. </font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(g)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">PC1 includes revenues from our contract manufacturing, including certain Comirnaty-related manufacturing activities performed on behalf of BioNTech ($5&#160;million and $47&#160;million for the first quarters of 2023 and 2022, respectively), and revenues from our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses&#47;partnerships.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(h)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Developed Europe region includes the following markets&#58; Western Europe, Scandinavian countries and Finland.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(i)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Developed Rest of World region includes the following markets&#58; Japan, South Korea, Canada, Australia and New Zealand.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(j)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Emerging Markets region includes, but is not limited to, the following markets&#58; Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Central Europe, the Middle East, Africa and Turkey.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">*</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Indicates calculation not meaningful.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Amounts may not add due to rounding. All percentages have been calculated using unrounded amounts.</font></td></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 24 -</font></div></div></div><div id="i3f14874d4dff44619437bc4e8219b905_76"></div><hr style="page-break-after:always"><div style="min-height:38.25pt;width:100%"><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><font><br></font></div></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DISCLOSURE NOTICE&#58; Except where otherwise noted, the information contained in this earnings release and the related attachments is as of May&#160;2, 2023. We assume no obligation to update any forward-looking statements contained in this earnings release and the related attachments as a result of new information or future events or developments.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This earnings release and the related attachments contain forward-looking statements about, among other topics, our anticipated operating and financial performance&#59; reorganizations&#59; business plans, strategy and prospects&#59; our Environmental, Social and Governance (ESG) priorities, strategy and goals&#59; expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, launches, clinical trial results and other developing data, revenue contribution and projections, potential pricing and reimbursement, potential market dynamics and size, growth, performance, timing of exclusivity and potential benefits&#59; strategic reviews&#59; capital allocation objectives&#59; dividends and share repurchases&#59; plans for and prospects of our acquisitions, dispositions and other business development activities, including our proposed acquisition of Seagen, and our ability to successfully capitalize on these opportunities&#59; manufacturing and product supply&#59; our ongoing efforts to respond to COVID-19, including Comirnaty (as defined in this earnings release) and our oral COVID-19 treatment (Paxlovid)&#59; and our expectations regarding the impact of COVID-19 on our business, operations and financial results that involve substantial risks and uncertainties.&#160;You can identify these statements by the fact that they use future dates or use words such as &#8220;will,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;likely,&#8221; &#8220;ongoing,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;assume,&#8221; &#8220;target,&#8221; &#8220;forecast,&#8221; &#8220;guidance,&#8221; &#8220;goal,&#8221; &#8220;objective,&#8221; &#8220;aim,&#8221; &#8220;seek,&#8221; &#8220;potential,&#8221; &#8220;hope&#8221; and other words and terms of similar meaning. </font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among the factors that could cause actual results to differ materially from past results and future plans and projected future results are the following&#58;</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to Our Business, Industry and Operations, and Business Development&#58;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the outcome of research and development (R&#38;D) activities, including, the ability to meet anticipated pre-clinical or clinical endpoints, commencement and&#47;or completion dates for our pre-clinical or clinical trials, regulatory submission dates, and&#47;or regulatory approval and&#47;or launch dates&#59; the possibility of unfavorable pre-clinical and clinical trial results, including the possibility of unfavorable new pre-clinical or clinical data and further analyses of existing pre-clinical or clinical data&#59; risks associated with preliminary, early stage or interim data&#59; the risk that pre-clinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review&#47;publication process, in the scientific community generally, and by regulatory authorities&#59; and whether and when additional data from our pipeline programs will be published in scientific journal publications and, if so, when and with what modifications and interpretations&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to successfully address comments received from regulatory authorities such as the FDA or the EMA, or obtain approval for new products and indications from regulators on a timely basis or at all&#59; regulatory decisions impacting labeling, including the scope of indicated patient populations, product dosage, manufacturing processes, safety and&#47;or other matters, including decisions relating to emerging developments regarding potential product impurities&#59; the impact of, or uncertainties regarding the ability to obtain, recommendations by technical or advisory committees&#59; and the timing of pricing approvals and product launches&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">claims and concerns that may arise regarding the safety or efficacy of in-line products and product candidates, including claims and concerns that may arise from the outcome of post-approval clinical trials, which could impact marketing approval, product labeling, and&#47;or availability or commercial potential, including uncertainties regarding the commercial or other impact of the results of the Xeljanz ORAL Surveillance (A3921133) study or actions by regulatory authorities based on analysis of ORAL Surveillance or other data, including on other Janus kinase (JAK) inhibitors in our portfolio&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the success and impact of external business development activities, including the ability to identify and execute on potential business development opportunities&#59; the ability to satisfy the conditions to closing of announced transactions in the anticipated time frame or at all&#59; the ability to realize the anticipated benefits of any such transactions in the anticipated time frame or at all&#59; the potential need for and impact of additional equity or debt financing to pursue these opportunities, which could result in increased leverage and&#47;or a downgrade of our credit ratings&#59; challenges integrating the businesses and operations&#59; disruption to business and operations relationships&#59; risks related to growing revenues for certain acquired products&#59; significant transaction costs&#59; and unknown liabilities&#59; </font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">risks and uncertainties related to Pfizer&#8217;s proposed acquisition of Seagen, including, among other things, risks related to the satisfaction or waiver of the conditions to closing the proposed acquisition (including the failure to obtain necessary regulatory approvals and failure to obtain the requisite vote by Seagen stockholders) in the anticipated timeframe or at all, including the possibility that the proposed acquisition does not close&#59; the possibility that competing offers may be made&#59; risks related to the ability to realize the anticipated benefits of the proposed acquisition, including the possibility that the expected benefits from the acquisition will not be realized or will not be realized within the expected time period&#59; the risk that the businesses will not be integrated successfully&#59; disruption from the transaction making it more difficult to maintain business and operational relationships&#59; negative effects of the announcement or the consummation of the </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 25 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:38.25pt;width:100%"><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><font><br></font></div></div><div style="margin-bottom:3pt;padding-left:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proposed acquisition on the market price of Pfizer&#8217;s common stock and&#47;or operating results&#59; significant transaction costs&#59; unknown liabilities&#59; the risk of litigation and&#47;or regulatory actions related to the proposed acquisition or Seagen&#8217;s business&#59; risks related to the financing of the transaction&#59; other business effects and uncertainties, including the effects of industry, market, business, economic, political or regulatory conditions&#59; future exchange and interest rates&#59; changes in tax and other laws, regulations, rates and policies&#59; the impact of the proposed acquisition on future business combinations or disposals&#59; uncertainties regarding the commercial success of Pfizer&#8217;s and Seagen&#8217;s commercialized and pipeline products&#59; the uncertainties inherent in R&#38;D&#59; whether and when drug applications may be filed in any jurisdictions for Pfizer&#8217;s or Seagen&#8217;s pipeline products&#59; whether and when any such applications may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether any such products will be commercially successful&#59; and competitive developments&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">competition, including from new product entrants, in-line branded products, generic products, private label products, biosimilars and product candidates that treat or prevent diseases and conditions similar to those treated or intended to be prevented by our in-line products and product candidates&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the ability to successfully market both new and existing products, including biosimilars&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">difficulties or delays in manufacturing, sales or marketing&#59; supply disruptions, shortages or stock-outs at our facilities or third-party facilities that we rely on&#59; and legal or regulatory actions&#59; </font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the impact of public health outbreaks, epidemics or pandemics (such as COVID-19) on our business, operations and financial condition and results, including impacts on our employees, manufacturing, supply chain, sales and marketing, R&#38;D and clinical trials&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">risks and uncertainties related to our efforts to develop and commercialize our COVID-19 products, as well as challenges related to their manufacturing, supply and distribution, including, among others, uncertainties inherent in R&#38;D, including the ability to meet anticipated clinical endpoints, commencement and&#47;or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and&#47;or launch dates, as well as risks associated with pre-clinical and clinical data (including Phase 1&#47;2&#47;3 or Phase 4 data for Comirnaty, any monovalent, bivalent or variant-adapted vaccine candidates or any other vaccine candidate in the BNT162 program or Paxlovid or any future COVID-19 treatment) in any of our studies in pediatrics, adolescents or adults or real world evidence, including the possibility of unfavorable new pre-clinical, clinical or safety data and further analyses of existing pre-clinical, clinical or safety data or further information regarding the quality of pre-clinical, clinical or safety data, including by audit or inspection&#59; the ability to produce comparable clinical or other results for Comirnaty, any monovalent, bivalent or variant-adapted vaccine candidates or other vaccines that may result from the BNT162 program, Paxlovid or any future COVID-19 treatment or any other COVID-19 program, including the rate of effectiveness and&#47;or efficacy, safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial for any such products and additional studies, in real-world data studies or in larger, more diverse populations following commercialization&#59; the ability of Comirnaty, any monovalent, bivalent or variant-adapted vaccine candidates or any future vaccine to prevent, or Paxlovid or any future COVID-19 treatment to be effective against, COVID-19 caused by emerging virus variants&#59; the risk that demand for any products may be reduced, no longer exist or not meet expectations, which may lead to excess inventory on-hand and&#47;or in the channel or reduced revenues&#59; challenges related to a transition to the commercial market for any of our products&#59; uncertainties related to the public&#8217;s adherence to vaccines, boosters and treatments&#59; the risk that use of Comirnaty or Paxlovid will lead to new information about efficacy, safety or other developments, including the risk of additional adverse reactions, some of which may be serious&#59; the risk that pre-clinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review&#47;publication process, in the scientific community generally, and by regulatory authorities&#59; whether and when additional data from the BNT162 mRNA vaccine program, Paxlovid or other COVID-19 programs will be published in scientific journal publications and, if so, when and with what modifications and interpretations&#59; whether regulatory authorities will be satisfied with the design of and results from existing or future pre-clinical and clinical studies&#59; whether and when submissions to request emergency use or conditional marketing authorizations for Comirnaty or any future vaccines in additional populations, for a potential booster dose for Comirnaty, any monovalent or bivalent vaccine candidates or any potential future vaccines (including potential future annual boosters or re-vaccinations), and&#47;or biologics license and&#47;or EUA applications or amendments to any such applications may be filed in particular jurisdictions for Comirnaty, any monovalent or bivalent vaccine candidates or any other potential vaccines that may arise from the BNT162 program, including a potential variant-based, higher dose, or bivalent vaccine or any other potential vaccines, and if obtained, whether or when such EUA or licenses, or existing EUAs, will expire or terminate&#59; whether and when submissions to request emergency use or conditional marketing authorizations for Paxlovid or any future COVID-19 treatment and&#47;or any drug applications and&#47;or EUA applications or amendments to any such applications for any indication for Paxlovid or any future COVID-19 treatment may be filed in particular jurisdictions, and if obtained, whether or when such EUA or licenses, or existing EUAs, will expire or terminate&#59; whether and when any application that may be pending or filed for Comirnaty, any monovalent, bivalent or variant-adapted vaccine candidates or other vaccines that may result from the BNT162 program, Paxlovid or </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 26 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:38.25pt;width:100%"><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><font><br></font></div></div><div style="margin-bottom:3pt;padding-left:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any future COVID-19 treatment or any other COVID-19 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine&#8217;s or drug&#8217;s benefits outweigh its known risks and determination of the vaccine&#8217;s or drug&#8217;s efficacy and, if approved, whether it will be commercially successful&#59; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and&#47;or other matters that could affect the availability or commercial potential of a vaccine or drug, including the authorization or approval of products or therapies developed by other companies&#59; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers, including our relationship with BioNTech&#59; the risk that other companies may produce superior or competitive products&#59; risks related to the availability of raw materials to manufacture or test any such products&#59; challenges related to our vaccine&#8217;s formulation, dosing schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer&#59; challenges and risks related to medication errors such as prescribing or dispensing the wrong strength, improper dosing and self-administration errors&#59; the risk that we may not be able to successfully develop other vaccine formulations, booster doses or potential future annual boosters or re-vaccinations or new variant-based or next generation vaccines, potential combination respiratory vaccines or next generation COVID-19 treatments&#59; the risk that we may not be able to recoup costs associated with our R&#38;D and manufacturing efforts&#59; risks associated with any changes in the way we approach or provide research funding for the BNT162 program, Paxlovid or any other COVID-19 program&#59; challenges and risks associated with the pace of our development programs&#59; the risk that we may not be able to maintain manufacturing capacity or access to logistics or supply channels commensurate with global demand for our COVID-19 products, which would negatively impact our ability to supply our COVID-19 products within the projected time periods&#59; risks related to our ability to achieve our revenue forecasts for Comirnaty and Paxlovid or any potential future COVID-19 vaccines or treatments&#59; whether and when additional supply or purchase agreements will be reached or existing agreements will be completed or renegotiated&#59; uncertainties regarding the ability to obtain recommendations from vaccine or treatment advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations&#59; pricing and access challenges for such products&#59; challenges related to public confidence in, or awareness of Comirnaty or Paxlovid, including challenges driven by misinformation or disinformation, access, concerns about clinical data integrity, or prescriber and pharmacy education&#59; uncertainties around future changes to applicable healthcare policies and guidelines issued by the U.S. federal government in connection with the declared termination of the federal government&#8217;s COVID-19 public health emergency as of May 11, 2023&#59; trade restrictions&#59; potential third-party royalties or other claims related to Comirnaty or Paxlovid&#59; and competitive developments&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">trends toward managed care and healthcare cost containment, and our ability to obtain or maintain timely or adequate pricing or favorable formulary placement for our products&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">interest rate and foreign currency exchange rate fluctuations, including the impact of possible currency devaluations and monetary policy actions in countries experiencing high inflation rates&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">any significant issues involving our largest wholesale distributors or government customers, which account for a substantial portion of our revenues&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the impact of the increased presence of counterfeit medicines or vaccines in the pharmaceutical supply chain&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">any significant issues related to the outsourcing of certain operational and staff functions to third parties&#59; and any significant issues related to our JVs and other third-party business arrangements&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">uncertainties related to general economic, political, business, industry, regulatory and market conditions including, without limitation, uncertainties related to the impact on us, our customers, suppliers and lenders and counterparties to our foreign-exchange and interest-rate agreements of challenging global economic conditions, such as inflation, and recent and possible future changes in global financial markets&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">any changes in business, political and economic conditions due to actual or threatened terrorist activity, geopolitical instability, civil unrest or military action&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the impact of product recalls, withdrawals and other unusual items, including uncertainties related to regulator-directed risk evaluations and assessments, including our ongoing evaluation of our product portfolio for the potential presence or formation of nitrosamines&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">trade buying patterns&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the risk of an impairment charge related to our intangible assets, goodwill or equity-method investments&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the impact of, and risks and uncertainties related to, restructurings and internal reorganizations, as well as any other corporate strategic initiatives and growth strategies, and cost-reduction and productivity initiatives, each of which requires upfront costs but may fail to yield anticipated benefits and may result in unexpected costs or organizational disruption&#59;</font></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the ability to successfully achieve our climate goals and progress our environmental sustainability priorities&#59;</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 27 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:38.25pt;width:100%"><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><font><br></font></div></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to Government Regulation and Legal Proceedings&#58;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the impact of any U.S. healthcare reform or legislation or any significant spending reductions or cost controls affecting Medicare, Medicaid or other publicly funded or subsidized health programs, including the Inflation Reduction Act of 2022, or changes in the tax treatment of employer-sponsored health insurance that may be implemented&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">U.S. federal or state legislation or regulatory action and&#47;or policy efforts affecting, among other things, pharmaceutical product pricing, intellectual property, reimbursement or access or restrictions on U.S. direct-to-consumer advertising&#59; limitations on interactions with healthcare professionals and other industry stakeholders&#59; as well as pricing pressures for our products as a result of highly competitive insurance markets&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">legislation or regulatory action in markets outside of the U.S., such as China and Europe, including, without limitation, laws related to pharmaceutical product pricing, intellectual property, regulatory data protection, environmental impact of medicines, reimbursement or access, including, in particular, continued government-mandated reductions in prices and access restrictions for certain biopharmaceutical products to control costs in those markets&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the exposure of our operations globally to possible capital and exchange controls, economic conditions, expropriation and other restrictive government actions, changes in intellectual property legal protections and remedies, the impact of political or civil unrest or military action, including the ongoing conflict between Russia and Ukraine and its economic consequences, unstable governments and legal systems, inter-governmental disputes and natural disasters or disruptions related to climate change&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">legal defense costs, insurance expenses, settlement costs and contingencies, including those related to actual or alleged environmental contamination&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the risk and impact of an adverse decision or settlement and the risk related to adequacy of reserves related to legal proceedings&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the risk and impact of tax related litigation and investigations&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">governmental laws and regulations affecting our operations, including, without limitation, the recently enacted Inflation Reduction Act of 2022, changes in laws and regulations or their interpretation, including, among others, changes in tax laws and regulations internationally and in the U.S., the adoption of global minimum taxation requirements outside the U.S. and potential changes to existing tax law by the current U.S. Presidential administration and Congress&#59;</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to Intellectual Property, Technology and Security&#58;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">any significant breakdown or interruption of our information technology systems and infrastructure (including cloud services)&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">any business disruption, theft of confidential or proprietary information, security threats on facilities or infrastructure, extortion or integrity compromise resulting from a cyber-attack or other malfeasance by, but not limited to, nation states, employees, business partners or others&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the risk that our currently pending or future patent applications may not be granted on a timely basis or at all, or any patent-term extensions that we seek may not be granted on a timely basis, if at all&#59; and</font></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">risks to our products, patents and other intellectual property, such as&#58; (i) claims of invalidity that could result in loss of exclusivity&#59; (ii) claims of patent infringement, including asserted and&#47;or unasserted intellectual property claims&#59; (iii) claims we may assert against intellectual property rights held by third parties&#59; (iv) challenges faced by our collaboration or licensing partners to the validity of their patent rights&#59; or (v) any pressure, or legal or regulatory action by, various stakeholders or governments that could potentially result in us not seeking intellectual property protection or agreeing not to enforce or being restricted from enforcing intellectual property rights related to our products, including Comirnaty and Paxlovid.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot guarantee that any forward-looking statement will be realized. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and in our subsequent report on Form 10-Q, in each case including in the sections thereof captioned &#8220;Forward-Looking Information and Factors That May Affect Future Results&#8221; and &#8220;Item 1A. Risk Factors,&#8221; and in our subsequent reports on Form 8-K.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This earnings release may include discussion of certain clinical studies relating to various in-line products and&#47;or product candidates. These studies typically are part of a larger body of clinical data relating to such products or product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and&#47;or effectiveness of a product candidate or a new indication for an in-line product, regulatory authorities may not share our views and may require additional data or may deny approval altogether.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 28 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:38.25pt;width:100%"><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information contained on our website or any third-party website is not incorporated by reference into this earnings release. All trademarks mentioned are the property of their owners. </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 29 -</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>pfe-20230502.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:3bfb6b0d-6e8d-4cb0-a62e-0371898ecb32,g:1009c864-99f1-4bb4-ae0b-fc6fb1dc1c0e-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:pfe="http://www.pfizer.com/20230502" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.pfizer.com/20230502">
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pfe-20230502_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pfe-20230502_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pfe-20230502_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.pfizer.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="pfe_NotesDue20271.000Member" abstract="true" name="NotesDue20271.000Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>pfe-20230502_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:3bfb6b0d-6e8d-4cb0-a62e-0371898ecb32,g:1009c864-99f1-4bb4-ae0b-fc6fb1dc1c0e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/CoverPage" xlink:type="simple" xlink:href="pfe-20230502.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/CoverPage" xlink:type="extended" id="i817d92a98e29491aa078c72a8ea0780d_CoverPage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_b839f9ea-81bb-4298-828f-b0c84a5ec73d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:to="loc_dei_Security12bTitle_b839f9ea-81bb-4298-828f-b0c84a5ec73d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_7e7fe01c-2ba0-4011-84cc-aa9e26b0c2b4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:to="loc_dei_DocumentType_7e7fe01c-2ba0-4011-84cc-aa9e26b0c2b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_153f702b-0393-4e65-880a-23b36513c03a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:to="loc_dei_DocumentPeriodEndDate_153f702b-0393-4e65-880a-23b36513c03a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_16ef518b-8a5c-4a37-9ca0-8ca1a733df17" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:to="loc_dei_EntityRegistrantName_16ef518b-8a5c-4a37-9ca0-8ca1a733df17" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_6e2e88c5-c643-4520-bd58-0b6c37c6cf65" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:to="loc_dei_EntityIncorporationStateCountryCode_6e2e88c5-c643-4520-bd58-0b6c37c6cf65" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_1267b014-95b1-497e-92e5-3245dcb82722" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:to="loc_dei_EntityFileNumber_1267b014-95b1-497e-92e5-3245dcb82722" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_3fed2c5a-d361-4cd7-82d5-782777d7b124" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:to="loc_dei_EntityTaxIdentificationNumber_3fed2c5a-d361-4cd7-82d5-782777d7b124" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_5ac44972-f56c-4b20-bffa-48ca9f95e30f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:to="loc_dei_EntityAddressAddressLine1_5ac44972-f56c-4b20-bffa-48ca9f95e30f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_f6f46bfe-87a3-4d5a-9799-a995cb063fba" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:to="loc_dei_EntityAddressCityOrTown_f6f46bfe-87a3-4d5a-9799-a995cb063fba" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_eb6d7214-9476-48fc-9de8-ea1c87ee023e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:to="loc_dei_EntityAddressStateOrProvince_eb6d7214-9476-48fc-9de8-ea1c87ee023e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_b5564cbf-65e4-4f67-a809-afc7194608f1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:to="loc_dei_EntityAddressPostalZipCode_b5564cbf-65e4-4f67-a809-afc7194608f1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_82dff20c-7444-4d6c-949c-3d47021abf4f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:to="loc_dei_CityAreaCode_82dff20c-7444-4d6c-949c-3d47021abf4f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_8e25f4c9-7284-403d-8616-0b320945f108" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:to="loc_dei_LocalPhoneNumber_8e25f4c9-7284-403d-8616-0b320945f108" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_45884f3f-7837-4b28-904b-cce5248fb520" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:to="loc_dei_WrittenCommunications_45884f3f-7837-4b28-904b-cce5248fb520" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_17ac881b-d0d7-4d93-a890-41106ac5f485" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:to="loc_dei_SolicitingMaterial_17ac881b-d0d7-4d93-a890-41106ac5f485" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_8476ab0b-d548-47d6-9034-dd29ddfe9dbe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:to="loc_dei_PreCommencementTenderOffer_8476ab0b-d548-47d6-9034-dd29ddfe9dbe" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_a4d60da5-e402-4b8a-8d62-54a2d17772e6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_a4d60da5-e402-4b8a-8d62-54a2d17772e6" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_4194e08e-2125-4d4a-887f-396d1527f20f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:to="loc_dei_EntityEmergingGrowthCompany_4194e08e-2125-4d4a-887f-396d1527f20f" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_06a08eec-20ff-411e-a3c2-00c1ea9f918a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:to="loc_dei_AmendmentFlag_06a08eec-20ff-411e-a3c2-00c1ea9f918a" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_35515e1a-2e98-4694-8d04-489763c62cca" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:to="loc_dei_EntityCentralIndexKey_35515e1a-2e98-4694-8d04-489763c62cca" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b05b384c-b631-4027-b9d7-b60182db23f7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:to="loc_dei_TradingSymbol_b05b384c-b631-4027-b9d7-b60182db23f7" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_3441e7a4-8d8d-4962-ac42-c45d16e5adeb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:to="loc_dei_SecurityExchangeName_3441e7a4-8d8d-4962-ac42-c45d16e5adeb" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_1d87c4a1-5fb9-4207-80c9-2d5af31ce0eb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:to="loc_dei_EntitiesTable_1d87c4a1-5fb9-4207-80c9-2d5af31ce0eb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_341d2bd0-0b30-4b7d-b30a-07bce05e275b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_1d87c4a1-5fb9-4207-80c9-2d5af31ce0eb" xlink:to="loc_us-gaap_StatementClassOfStockAxis_341d2bd0-0b30-4b7d-b30a-07bce05e275b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_341d2bd0-0b30-4b7d-b30a-07bce05e275b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_341d2bd0-0b30-4b7d-b30a-07bce05e275b" xlink:to="loc_us-gaap_ClassOfStockDomain_341d2bd0-0b30-4b7d-b30a-07bce05e275b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_50f1af27-3415-4894-a2ef-0aee9c745a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_341d2bd0-0b30-4b7d-b30a-07bce05e275b" xlink:to="loc_us-gaap_ClassOfStockDomain_50f1af27-3415-4894-a2ef-0aee9c745a8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c0e1e138-d381-4206-9569-5dd2cf5e808a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_50f1af27-3415-4894-a2ef-0aee9c745a8e" xlink:to="loc_us-gaap_CommonStockMember_c0e1e138-d381-4206-9569-5dd2cf5e808a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NotesDue20271.000Member_57a04b7d-52fd-405c-82bf-fe71c9477a67" xlink:href="pfe-20230502.xsd#pfe_NotesDue20271.000Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_50f1af27-3415-4894-a2ef-0aee9c745a8e" xlink:to="loc_pfe_NotesDue20271.000Member_57a04b7d-52fd-405c-82bf-fe71c9477a67" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>pfe-20230502_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:3bfb6b0d-6e8d-4cb0-a62e-0371898ecb32,g:1009c864-99f1-4bb4-ae0b-fc6fb1dc1c0e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_0e4df621-aabe-4c12-8acd-815f2a4e5374_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_3a1f2c04-b1c4-4111-9ddd-c46b0b852037_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_d36b5f87-1e8f-4f87-b456-db7a3d3470ee_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_d18b8a33-a839-4a3c-aedf-0082801e9ba4_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_469d9cc5-be7a-4324-948b-68ee7d716b64_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_NotesDue20271.000Member_77548397-0f8f-41a7-b238-c164bba9ea39_terseLabel_en-US" xlink:label="lab_pfe_NotesDue20271.000Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2027, 1.000% [Member]</link:label>
    <link:label id="lab_pfe_NotesDue20271.000Member_label_en-US" xlink:label="lab_pfe_NotesDue20271.000Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2027, 1.000% [Member]</link:label>
    <link:label id="lab_pfe_NotesDue20271.000Member_documentation_en-US" xlink:label="lab_pfe_NotesDue20271.000Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2027, 1.000% [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NotesDue20271.000Member" xlink:href="pfe-20230502.xsd#pfe_NotesDue20271.000Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_NotesDue20271.000Member" xlink:to="lab_pfe_NotesDue20271.000Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_37209f8e-68ff-46b9-bdb4-1fb157045e66_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_d81c44e3-50a0-47ae-b805-8ffdcd5ba380_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_4ac05449-caba-40ac-99ab-fda1df313818_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_a03fa61b-0429-4bed-a757-f577fe481397_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_0dd2f7c9-bdf1-4683-a5bf-8b16bc763cda_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_b8535554-281b-41ba-b317-a693dbea98db_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_b19f430e-9895-44dd-8060-43e3730fbe02_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_546a1e9d-edad-49f1-9034-c024422b01b5_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_3c142f73-8767-446b-8e6d-4eded3902f18_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_3a4fd917-d7db-4d2c-8503-148471a05d26_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_50d57d47-dd19-4d5a-a886-ccfc1fa67219_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_5ee8ad42-afaf-47f5-a6b2-0602bca5278b_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_b905d17a-1a1a-4d72-b7a0-2979f5ee4e45_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_16bf21fb-6038-4365-b4bb-fcd4b04f89f9_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_9e282e13-c713-4153-89d7-a091f5c886eb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_32e73234-90e8-4397-b9a3-b9d5be6b0216_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_bcdb9f31-ae7d-49a8-9f23-72a7a1460fe0_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_2561c4c9-a511-45f5-b84d-ab0bce8a5357_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_fbf861d3-34c5-4e5e-94aa-2dea121796e4_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_0a1631b2-a73f-4aab-902a-d40c7d63fc5e_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_68cef175-b163-41a2-8f63-b078c6963377_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_14da595f-0ab0-4236-aed5-f8b504bad9de_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_aff9c92d-9b74-4138-8e8a-43e58ec9cc67_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>pfe-20230502_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:3bfb6b0d-6e8d-4cb0-a62e-0371898ecb32,g:1009c864-99f1-4bb4-ae0b-fc6fb1dc1c0e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.pfizer.com/role/CoverPage" xlink:type="simple" xlink:href="pfe-20230502.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_749003ee-581f-4249-81d4-a59ae64e3fee" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_1d87c4a1-5fb9-4207-80c9-2d5af31ce0eb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_749003ee-581f-4249-81d4-a59ae64e3fee" xlink:to="loc_dei_EntitiesTable_1d87c4a1-5fb9-4207-80c9-2d5af31ce0eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_341d2bd0-0b30-4b7d-b30a-07bce05e275b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_1d87c4a1-5fb9-4207-80c9-2d5af31ce0eb" xlink:to="loc_us-gaap_StatementClassOfStockAxis_341d2bd0-0b30-4b7d-b30a-07bce05e275b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_50f1af27-3415-4894-a2ef-0aee9c745a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_341d2bd0-0b30-4b7d-b30a-07bce05e275b" xlink:to="loc_us-gaap_ClassOfStockDomain_50f1af27-3415-4894-a2ef-0aee9c745a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c0e1e138-d381-4206-9569-5dd2cf5e808a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_50f1af27-3415-4894-a2ef-0aee9c745a8e" xlink:to="loc_us-gaap_CommonStockMember_c0e1e138-d381-4206-9569-5dd2cf5e808a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NotesDue20271.000Member_57a04b7d-52fd-405c-82bf-fe71c9477a67" xlink:href="pfe-20230502.xsd#pfe_NotesDue20271.000Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_50f1af27-3415-4894-a2ef-0aee9c745a8e" xlink:to="loc_pfe_NotesDue20271.000Member_57a04b7d-52fd-405c-82bf-fe71c9477a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_1d87c4a1-5fb9-4207-80c9-2d5af31ce0eb" xlink:to="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_b839f9ea-81bb-4298-828f-b0c84a5ec73d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:to="loc_dei_Security12bTitle_b839f9ea-81bb-4298-828f-b0c84a5ec73d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_7e7fe01c-2ba0-4011-84cc-aa9e26b0c2b4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:to="loc_dei_DocumentType_7e7fe01c-2ba0-4011-84cc-aa9e26b0c2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_153f702b-0393-4e65-880a-23b36513c03a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:to="loc_dei_DocumentPeriodEndDate_153f702b-0393-4e65-880a-23b36513c03a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_16ef518b-8a5c-4a37-9ca0-8ca1a733df17" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:to="loc_dei_EntityRegistrantName_16ef518b-8a5c-4a37-9ca0-8ca1a733df17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_6e2e88c5-c643-4520-bd58-0b6c37c6cf65" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:to="loc_dei_EntityIncorporationStateCountryCode_6e2e88c5-c643-4520-bd58-0b6c37c6cf65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_1267b014-95b1-497e-92e5-3245dcb82722" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:to="loc_dei_EntityFileNumber_1267b014-95b1-497e-92e5-3245dcb82722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_3fed2c5a-d361-4cd7-82d5-782777d7b124" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:to="loc_dei_EntityTaxIdentificationNumber_3fed2c5a-d361-4cd7-82d5-782777d7b124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_5ac44972-f56c-4b20-bffa-48ca9f95e30f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:to="loc_dei_EntityAddressAddressLine1_5ac44972-f56c-4b20-bffa-48ca9f95e30f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_f6f46bfe-87a3-4d5a-9799-a995cb063fba" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:to="loc_dei_EntityAddressCityOrTown_f6f46bfe-87a3-4d5a-9799-a995cb063fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_eb6d7214-9476-48fc-9de8-ea1c87ee023e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:to="loc_dei_EntityAddressStateOrProvince_eb6d7214-9476-48fc-9de8-ea1c87ee023e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_b5564cbf-65e4-4f67-a809-afc7194608f1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:to="loc_dei_EntityAddressPostalZipCode_b5564cbf-65e4-4f67-a809-afc7194608f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_82dff20c-7444-4d6c-949c-3d47021abf4f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:to="loc_dei_CityAreaCode_82dff20c-7444-4d6c-949c-3d47021abf4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_8e25f4c9-7284-403d-8616-0b320945f108" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:to="loc_dei_LocalPhoneNumber_8e25f4c9-7284-403d-8616-0b320945f108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_45884f3f-7837-4b28-904b-cce5248fb520" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:to="loc_dei_WrittenCommunications_45884f3f-7837-4b28-904b-cce5248fb520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_17ac881b-d0d7-4d93-a890-41106ac5f485" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:to="loc_dei_SolicitingMaterial_17ac881b-d0d7-4d93-a890-41106ac5f485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_8476ab0b-d548-47d6-9034-dd29ddfe9dbe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:to="loc_dei_PreCommencementTenderOffer_8476ab0b-d548-47d6-9034-dd29ddfe9dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_a4d60da5-e402-4b8a-8d62-54a2d17772e6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_a4d60da5-e402-4b8a-8d62-54a2d17772e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_4194e08e-2125-4d4a-887f-396d1527f20f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:to="loc_dei_EntityEmergingGrowthCompany_4194e08e-2125-4d4a-887f-396d1527f20f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_06a08eec-20ff-411e-a3c2-00c1ea9f918a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:to="loc_dei_AmendmentFlag_06a08eec-20ff-411e-a3c2-00c1ea9f918a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_35515e1a-2e98-4694-8d04-489763c62cca" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:to="loc_dei_EntityCentralIndexKey_35515e1a-2e98-4694-8d04-489763c62cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b05b384c-b631-4027-b9d7-b60182db23f7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:to="loc_dei_TradingSymbol_b05b384c-b631-4027-b9d7-b60182db23f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_3441e7a4-8d8d-4962-ac42-c45d16e5adeb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9a3a33-ca52-4368-9c18-417905c84d5d" xlink:to="loc_dei_SecurityExchangeName_3441e7a4-8d8d-4962-ac42-c45d16e5adeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>pfizerlogoa.jpg
<TEXT>
begin 644 pfizerlogoa.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1"B17AI9@  34T *@    @ ! $[  (
M   0   (2H=I  0    !   (6IR=  $    @   0>NH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %)O<V5N+"!0
M96YN>2!3+@   >H<  <   @,   (;      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#!04$!
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\%BH?%3?W,Q**FFM;BW8K<021,.H=",5#72FGJCE::T84444Q!1110 4444
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MEC*?/3^:["T445Q'<%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=-*HW[K/9****^(.D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M75VV;JYFG/K)(6_G4%%>C"C2I_!%+T1YLZU6I\<F_5A1116ID%%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHHH **** "BBB@ HHHH **** .T^%VG&\\7BX(REG$TASZGY1_,_E7M5>?\
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M]_$!.NK1/_O6L?\ 05B^%<:MI1^]_P"0_;Q/L&BOD5?VA/'PZWMH?K:K2_\
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M'Y5\S>+?'GB#QK?&XUR^>1,YCMD.V*,>@7^IYKG*^GPG"M-1YL3*[[+;[_\
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MAQM%%%??G*=K\']6_L?XL:%.6PDUQ]F;W\P%!^I%?:E?!?A:0Q>,-&D7JE_
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MQP$6]Y7?^7X(QJN\PHHHKWS(*^O_ (%>$!X7^'5O<SQE+[5<74V>H4C]VO\
MWSS]6-?+_@;P_P#\)3XYTG1BK-'=7"B;;U$8^9S_ -\@U]T1QK%$L<:A410J
MJ.@ KXOBK%N,(8:/75^G3\?R.BA'6XZBBBO@#J"BBB@ HHHH **** "BBB@
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M2U7:UO:H)!_MD9;]2:WJ**_$ZDW4FYRW;N>BM$%%%%0,**** "BBB@ HHHH
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M#L4?3Y2?QKU6OR;/<1[?,*CZ+3[O^#<[J2M!!1117BF@4444 %%%% !1110
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MU;3M7@\[2KZVO(_[]O*KC]#5NO'<7%V9H%%%%( HHHH **** "BBB@ HHHH
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MWMY+_-F-6I=V04445]88!1110 ])9(\^7(R9Z[6(IWVJX_Y[R?\ ?9J*BBR
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M %(RAE*GH1@TM% '"M\%OA^[%F\.0EB<DF:7G_QZD_X4I\/?^A;A_P"_TO\
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M_O\ 2_\ Q5=W11_:&,_Y^R_\"?\ F'+'L9^AZ#IGAK28]-T2T6TLXR66)22
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M+_\ %5W=%']H8S_G[+_P)_YARQ['"?\ "E/A[_T+</\ W^E_^*H_X4I\/?\
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MU&*V04445QE&3XB\+Z/XLT]+'Q!9K>6R2"58V=E 8 @'Y2.Q-<U_PI3X>_\
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ME!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%>%_M.Z[]G\/:3HD3X:ZG,\JC^Z@P/U;]*]TKY"^/NN_VQ\5+N!&S%IL:VJ_
M4?,WZL1^%?0\.X?VV/C)[1N_T7XLRJNT3S.BBBOU(X@JUI=A)JFKV=A "9+J
M=(5QZLP']:JUZ5\!-"&L_%6SED3=#I\;W3<< @87_P >(_*N;%UUA\/.J_LI
ML<5=V/K;3;&/3-*M;& 8BMH4B0#T4 #^56:**_%FVW=GHA1112 **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@!&17&'4,/0C-85]X%\*:FS-?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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84 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140090691998688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>May 02, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  02,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PFIZER INC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-3619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-5315170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">66 Hudson Boulevard East<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York,<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10001-2192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">733-2323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000078003<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.05 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PFE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pfe_NotesDue20271.000Member', window );">Notes Due 2027, 1.000% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.000% Notes due 2027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PFE27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pfe_NotesDue20271.000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pfe_NotesDue20271.000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>pfe-20230502_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pfe="http://www.pfizer.com/20230502"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="pfe-20230502.xsd" xlink:type="simple"/>
    <context id="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <startDate>2023-05-02</startDate>
            <endDate>2023-05-02</endDate>
        </period>
    </context>
    <context id="iebb1578a148d4edf8114dad39708811d_D20230502-20230502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-02</startDate>
            <endDate>2023-05-02</endDate>
        </period>
    </context>
    <context id="i3ad3ddec41e540859df4e6108778cc03_D20230502-20230502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pfe:NotesDue20271.000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-02</startDate>
            <endDate>2023-05-02</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF80L2ZyYWc6MjczOGFjNjlkZDFkNGI5NTg5NjQ2MjdhODUwZmYxOTcvdGFibGU6NDJjM2MyYjc1OWI0NDg0YmEwOTQ5MDg3YzgxODg5MzkvdGFibGVyYW5nZTo0MmMzYzJiNzU5YjQ0ODRiYTA5NDkwODdjODE4ODkzOV8xLTEtMS0xLTYxNDg4Nw_02b8d0dc-e690-4599-9544-e85b50bf1046">0000078003</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF80L2ZyYWc6MjczOGFjNjlkZDFkNGI5NTg5NjQ2MjdhODUwZmYxOTcvdGFibGU6NDJjM2MyYjc1OWI0NDg0YmEwOTQ5MDg3YzgxODg5MzkvdGFibGVyYW5nZTo0MmMzYzJiNzU5YjQ0ODRiYTA5NDkwODdjODE4ODkzOV8yLTEtMS0xLTYxNDg4Nw_b14d2887-eb2f-458a-bb02-6d2f26d05110">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGV4dHJlZ2lvbjplYzhjNThmMWNmZDM0YmQwYjMyN2ExNjVhMjM2ZjcyNV8yNzgw_470ac897-3acf-469f-b3ba-6dfe474e5034">8-K</dei:DocumentType>
    <dei:DocumentType
      contextRef="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGV4dHJlZ2lvbjplYzhjNThmMWNmZDM0YmQwYjMyN2ExNjVhMjM2ZjcyNV8yNzgw_af3d24b9-8345-4e39-b98d-8a108e6686bf">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGV4dHJlZ2lvbjplYzhjNThmMWNmZDM0YmQwYjMyN2ExNjVhMjM2ZjcyNV8yMjk_1c79eebe-e644-47b0-97a6-702ec00c65e4">2023-05-02</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGV4dHJlZ2lvbjplYzhjNThmMWNmZDM0YmQwYjMyN2ExNjVhMjM2ZjcyNV8yNzgx_29813641-588e-4a78-a030-d865dd7e6199">PFIZER INC</dei:EntityRegistrantName>
    <dei:EntityRegistrantName
      contextRef="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGV4dHJlZ2lvbjplYzhjNThmMWNmZDM0YmQwYjMyN2ExNjVhMjM2ZjcyNV8yNzgx_4072a101-eff5-48d2-b455-67b0ab481bf4">PFIZER INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGFibGU6MGI4NGFmOWU4ZDRmNGExZmE1NjAxNjdiYzRjMTk5ZmIvdGFibGVyYW5nZTowYjg0YWY5ZThkNGY0YTFmYTU2MDE2N2JjNGMxOTlmYl8wLTAtMS0xLTYxNDg4Nw_d558708d-7bc8-46fa-95e9-bd1bc8bc768a">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGFibGU6MGI4NGFmOWU4ZDRmNGExZmE1NjAxNjdiYzRjMTk5ZmIvdGFibGVyYW5nZTowYjg0YWY5ZThkNGY0YTFmYTU2MDE2N2JjNGMxOTlmYl8wLTEtMS0xLTYxNDg4Nw_45c2f30b-939c-41b5-8337-ac306f987816">1-3619</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGFibGU6MGI4NGFmOWU4ZDRmNGExZmE1NjAxNjdiYzRjMTk5ZmIvdGFibGVyYW5nZTowYjg0YWY5ZThkNGY0YTFmYTU2MDE2N2JjNGMxOTlmYl8wLTItMS0xLTYxNDg4Nw_15d6a986-283b-4dbe-8d98-fa09294099eb">13-5315170</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGFibGU6ZmJiOTUzYjUwOWU2NDYzMGFkMmZkNGI4YjU5NmUxZDQvdGFibGVyYW5nZTpmYmI5NTNiNTA5ZTY0NjMwYWQyZmQ0YjhiNTk2ZTFkNF8wLTAtMS0xLTYxNDg4Nw_dd13839d-bbb7-4091-b517-f65b7e0d894c">66 Hudson Boulevard East</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode
      contextRef="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGFibGU6ZmJiOTUzYjUwOWU2NDYzMGFkMmZkNGI4YjU5NmUxZDQvdGFibGVyYW5nZTpmYmI5NTNiNTA5ZTY0NjMwYWQyZmQ0YjhiNTk2ZTFkNF8wLTItMS0xLTYxNDg4Nw_8851aff6-4e36-43f5-8c6c-7fe5bc9419af">10001-2192</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown
      contextRef="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGFibGU6ZmJiOTUzYjUwOWU2NDYzMGFkMmZkNGI4YjU5NmUxZDQvdGFibGVyYW5nZTpmYmI5NTNiNTA5ZTY0NjMwYWQyZmQ0YjhiNTk2ZTFkNF8xLTAtMS0xLTYxNDg4Nw_cfd2e570-9e61-4224-8e0f-fb352e5c9b77">New York,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGFibGU6ZmJiOTUzYjUwOWU2NDYzMGFkMmZkNGI4YjU5NmUxZDQvdGFibGVyYW5nZTpmYmI5NTNiNTA5ZTY0NjMwYWQyZmQ0YjhiNTk2ZTFkNF8xLTEtMS0xLTYxNDg4Nw_6f06eb59-f1af-4614-bbe1-a609b37da267">NY</dei:EntityAddressStateOrProvince>
    <dei:CityAreaCode
      contextRef="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGV4dHJlZ2lvbjplYzhjNThmMWNmZDM0YmQwYjMyN2ExNjVhMjM2ZjcyNV8yNzgy_cb34bfd8-cb8d-458f-8a3c-5e5d47d0bd51">212</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGV4dHJlZ2lvbjplYzhjNThmMWNmZDM0YmQwYjMyN2ExNjVhMjM2ZjcyNV8yNzc1_e1498378-d223-4b7e-8128-cf2a63b988be">733-2323</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGV4dHJlZ2lvbjplYzhjNThmMWNmZDM0YmQwYjMyN2ExNjVhMjM2ZjcyNV8yNzc2_9ff77caa-0ae0-4594-bad5-0fa8c8a9def4">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGV4dHJlZ2lvbjplYzhjNThmMWNmZDM0YmQwYjMyN2ExNjVhMjM2ZjcyNV8yNzgz_4b960350-1f1f-4fd3-b772-e16d9ad1af48">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGV4dHJlZ2lvbjplYzhjNThmMWNmZDM0YmQwYjMyN2ExNjVhMjM2ZjcyNV8yNzc4_42f5fede-151f-46d5-aa6c-373c2667f33e">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGV4dHJlZ2lvbjplYzhjNThmMWNmZDM0YmQwYjMyN2ExNjVhMjM2ZjcyNV8yNzc3_3c13b83f-dd9d-47f5-a5dd-cd15af8e3310">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="iebb1578a148d4edf8114dad39708811d_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGFibGU6NWQyZTA5NGQ3NDNjNDFhYzg4Y2ZjMDBhZDc1ZjliODYvdGFibGVyYW5nZTo1ZDJlMDk0ZDc0M2M0MWFjODhjZmMwMGFkNzVmOWI4Nl8zLTAtMS0xLTYxNDg4Nw_07671daa-7140-4c7e-8f28-67ecf8f59fb7">Common Stock, $0.05 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="iebb1578a148d4edf8114dad39708811d_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGFibGU6NWQyZTA5NGQ3NDNjNDFhYzg4Y2ZjMDBhZDc1ZjliODYvdGFibGVyYW5nZTo1ZDJlMDk0ZDc0M2M0MWFjODhjZmMwMGFkNzVmOWI4Nl8zLTItMS0xLTYxNDg4Nw_09fe4974-992d-4fbe-908e-9fe78c8ccdd5">PFE</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="iebb1578a148d4edf8114dad39708811d_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGFibGU6NWQyZTA5NGQ3NDNjNDFhYzg4Y2ZjMDBhZDc1ZjliODYvdGFibGVyYW5nZTo1ZDJlMDk0ZDc0M2M0MWFjODhjZmMwMGFkNzVmOWI4Nl8zLTQtMS0xLTYxNDg4Nw_05a7af27-9c11-474c-8bac-43c953ee2caf">NYSE</dei:SecurityExchangeName>
    <dei:SecurityExchangeName
      contextRef="i3ad3ddec41e540859df4e6108778cc03_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGFibGU6NWQyZTA5NGQ3NDNjNDFhYzg4Y2ZjMDBhZDc1ZjliODYvdGFibGVyYW5nZTo1ZDJlMDk0ZDc0M2M0MWFjODhjZmMwMGFkNzVmOWI4Nl8zLTQtMS0xLTYxNDg4Nw_efad3c18-987e-47ac-960b-5b92fc8ba0f3">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i3ad3ddec41e540859df4e6108778cc03_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGFibGU6NWQyZTA5NGQ3NDNjNDFhYzg4Y2ZjMDBhZDc1ZjliODYvdGFibGVyYW5nZTo1ZDJlMDk0ZDc0M2M0MWFjODhjZmMwMGFkNzVmOWI4Nl80LTAtMS0xLTYxNDg4Nw_373c172f-9cbb-4f8c-89a5-c39392d123e5">1.000% Notes due 2027</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i3ad3ddec41e540859df4e6108778cc03_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGFibGU6NWQyZTA5NGQ3NDNjNDFhYzg4Y2ZjMDBhZDc1ZjliODYvdGFibGVyYW5nZTo1ZDJlMDk0ZDc0M2M0MWFjODhjZmMwMGFkNzVmOWI4Nl80LTItMS0xLTYxNDg4Nw_0bc78b3c-f1fa-4d4f-9242-8a574623939f">PFE27</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="iebb1578a148d4edf8114dad39708811d_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGFibGU6NWQyZTA5NGQ3NDNjNDFhYzg4Y2ZjMDBhZDc1ZjliODYvdGFibGVyYW5nZTo1ZDJlMDk0ZDc0M2M0MWFjODhjZmMwMGFkNzVmOWI4Nl80LTQtMS0xLTYxNDg4Nw_05a7af27-9c11-474c-8bac-43c953ee2caf">NYSE</dei:SecurityExchangeName>
    <dei:SecurityExchangeName
      contextRef="i3ad3ddec41e540859df4e6108778cc03_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGFibGU6NWQyZTA5NGQ3NDNjNDFhYzg4Y2ZjMDBhZDc1ZjliODYvdGFibGVyYW5nZTo1ZDJlMDk0ZDc0M2M0MWFjODhjZmMwMGFkNzVmOWI4Nl80LTQtMS0xLTYxNDg4Nw_efad3c18-987e-47ac-960b-5b92fc8ba0f3">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGV4dHJlZ2lvbjplYzhjNThmMWNmZDM0YmQwYjMyN2ExNjVhMjM2ZjcyNV8yNzc5_95b74812-dc2d-4ae7-b4bb-727ecfe55e28">false</dei:EntityEmergingGrowthCompany>
    <dei:DocumentPeriodEndDate
      contextRef="ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiNDdiNDVhZTJhNTRjZWQ4NWI0NzQ4YmY3ODllZDNkL3NlYzpkYjQ3YjQ1YWUyYTU0Y2VkODViNDc0OGJmNzg5ZWQzZF8xL2ZyYWc6ZWM4YzU4ZjFjZmQzNGJkMGIzMjdhMTY1YTIzNmY3MjUvdGFibGU6MmY5YzNjZDc1ODNhNGRhMjkyY2JjNDg0OTJkZTZhZmUvdGFibGVyYW5nZToyZjljM2NkNzU4M2E0ZGEyOTJjYmM0ODQ5MmRlNmFmZV8yLTItMS0xLTYxODExOS90ZXh0cmVnaW9uOjRiMTVhMjU3ZjY5ZjQzMzZiNTUzMmY4YTBkYjhmYWIyXzU0OTc1NTgxNDA5OQ_1c79eebe-e644-47b0-97a6-702ec00c65e4">2023-05-02</dei:DocumentPeriodEndDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M? :5I+CXS1@A[!:$W5,(;\-(D&D6/PE5!8)KT*;7H1<(3*^ Z9T"\\"?R22
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M='@//GL?)=-[*CG_5U/\!%!+ P04    " "Y0*)6EXJ[',     3 @  "P
M %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=
MOZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'
MTD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[P
MS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T
M>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( +E HE89117U-P$
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M'R:/6D;KW$JY]_!*MAQSCG^T_ %02P,$%     @ N4"B5B0>FZ*M    ^ $
M !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<[61/0Z#, R%KQ+E #50
MJ4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_OR4Z?:!1W;J"V\R1&:P;*
M9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI
M?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI
M5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0    ( +E HE9ED'F2&0$
M ,\#   3    6T-O;G1E;G1?5'EP97-=+GAM;*V334[#,!"%KQ)E6R4N+%B@
MIAM@"UUP 6-/&JO^DV=:TMLS3MI*H!(5A4VL>-Z\SYZ7K-Z/$;#HG?78E!U1
M?!0"50=.8ATB>*ZT(3E)_)JV(DJUDUL0]\OE@U#!$WBJ*'N4Z]4SM')OJ7CI
M>1M-\$V9P&)9/(W"S&I*&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N6%"*JX1<^1UP
MZGL[0$I&0[&1B5ZE8Y7HK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC JFQ R!GZ]%T
M,4TFGC",S[O9_,%F"LC*30H1.;$$?\>=(\G=560C2&2FKW@ALO7L^T%.6X.^
MD<WC_0QI-^2!8ECFS_A[QA?_&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#
M%     @ N4"B5@=!36*!    L0   !               ( !     &1O8U!R
M;W!S+V%P<"YX;6Q02P$"% ,4    " "Y0*)6X9 )9^\    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " "Y0*)6
MF5R<(Q &  "<)P  $P              @ '- 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( +E HE8%AN+2P@0  /X4   8              "
M@0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " "Y0*)6
MGZ ;\+$"  #B#   #0              @ $&#0  >&PO<W1Y;&5S+GAM;%!+
M 0(4 Q0    ( +E HE:7BKL<P    !,"   +              "  >(/  !?
M<F5L<R\N<F5L<U!+ 0(4 Q0    ( +E HE89117U-P$  "<"   /
M      "  <L0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "Y0*)6)!Z;
MHJT   #X 0  &@              @ $O$@  >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    " "Y0*)699!YDAD!  #/ P  $P
M    @ $4$P  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  !>
%%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="pfe-20230502.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="pfe-20230502.htm">pfe-20230502.htm</File>
    <File>pfe-04022023xex99.htm</File>
    <File>pfe-20230502.xsd</File>
    <File>pfe-20230502_def.xml</File>
    <File>pfe-20230502_lab.xml</File>
    <File>pfe-20230502_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "pfe-20230502.htm": {
   "axisCustom": 0,
   "axisStandard": 1,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 30
   },
   "contextCount": 3,
   "dts": {
    "definitionLink": {
     "local": [
      "pfe-20230502_def.xml"
     ]
    },
    "inline": {
     "local": [
      "pfe-20230502.htm"
     ]
    },
    "labelLink": {
     "local": [
      "pfe-20230502_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pfe-20230502_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "pfe-20230502.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 29,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 1,
   "memberStandard": 1,
   "nsprefix": "pfe",
   "nsuri": "http://www.pfizer.com/20230502",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20230502.htm",
      "contextRef": "ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.pfizer.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20230502.htm",
      "contextRef": "ic772d69e24294cc68381b99c6567cd8c_D20230502-20230502",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 2,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "pfe_NotesDue20271.000Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes Due 2027, 1.000% [Member]",
        "label": "Notes Due 2027, 1.000% [Member]",
        "terseLabel": "Notes Due 2027, 1.000% [Member]"
       }
      }
     },
     "localname": "NotesDue20271.000Member",
     "nsuri": "http://www.pfizer.com/20230502",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001628280-23-014759-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-014759-xbrl.zip
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MVY<]T+:II[:0>G:./"0JJI5NN\0X^UUPMWP%9RCC7Y&B"H_4NN]*1($]XX_
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M1Y'+$WJ!%%4)FL#E@%L#*@I#L@V)DT!NH+<*>T2,"(5+B*U27J,&,D;+!D6
M-^%95/V\0?W?:3" =!/V$)@,2!F'])(R:>!*R9&\(%)?;/1I F:/(VU':0$R
MRJ\GPFE*I&$6'NHLBKM* T$'5J$XE6F'L;BEEP(["UDZW4]T)TKK WPQX$3
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M=0^JL=)5^!BL8=^+H_.SP.IF.;ETILS)/F* +^]BH<.GLLV6GF[_42$C.&3
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M?MD%L[Y [7[=6UUUH3__U.Q^A$MQL0E C)(G(]AM:-O%,(K*I4U[(/TTGEP
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MZ3^6XU'X2* BX)GWIB_#:D-A X!UTA.%;X:O7JG]1.I2@;TOB;W?IK;!_Q2
M,O1*=A1^4&+TUYC_H+_&7#].H[C6RL#%8@Q7FG0P\?EW$;:*(EW='TU=P!+
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M91/<J>^:^C+2+<(*<5BA6X05U@@K9!.X.Q*O4;K!2%@3TA')*XQ)9D"40&=
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M"%RP)'60P)].;HZ)&7O*)3LGY,\N/O5N_@G,'%V2#^@4Q>(O09)#QH4L8<L
ME_2>&H$;^C*I_J 'TAZOD'UU9;0/UNFI2C1\OF?; 7QT(8AE2>/5@(.;F+8]
MIWNH?2A/:QSV(A^N$&Y9LB<4:T$_Y':+)* Z%QTZ7,XP/3T@A%#YZ%'>IF*D
MOBE2B>*1]Q5=QLJ9S1,NW,0*B4 H[C56$HC_)EAO*%,*IOJ23/4__/XO0&R?
M'?W%[\40M"G;SPU3S1*=B=V!X5%*B0@ 13BQW@"H3\?@&6 9:HEE<H@@M8"
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M%+WL-#J%*A*8$>A'P.SPD]-Z.1(J?5.I:CII4GT'-+^C3UZO?UQ:[").=V5
M8IAXE*J4* QGF*]O3D"HCJ<@FL:<'=W<7%P</^Y03CH_04+/NG!SZ6>N[-0
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M1EP$FU(R\3R\&R^A[]F YBD@D)6-RA:MOWY&5V>?,KI.'!<N!.W.8N[##GQ
M88>ME;F^IL](3A +1?($760 I$*.7&KW"$\/72%U?NDC>1B9L*!:BA1\KO\9
MF,"P;@7'X/VYK5> 1MC0<OI ;'T3E?N136FM8:Z,5(N(A2"QEL+4,%6;[HSA
MY3@P!E[BH1/%]M 8(3TE+$X8ASWKI'O\;:U&#5IT[HU060IWXXV0ETKGK&3
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M1C-TZ-_:1]DD'/5R68(MTW+A+DMJ1F6R^7;4[Q>S3K)T^<[ZU),Z^<I%XV%
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MT02'TU#' #D1C$5<@QO-9,5DL'[@F53GEW17)Q*4/*DAXCIA#A,Y7%#OQ/[
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M@3\[[IAIU?(_*VQ).N92I&6DF5*B#VB>?EFW' ]HW?@C\'S:1%;B;N:(N$_
M@N5P8CYV CNFV!3 $V &#ACF/@&F<L]SX"+P&9NH9\RGQ#_A<,P("%0NK(LG
M!3T,>"  %54JT%,]-N+W.)E&V'&PU&#(:X8LL.EG\&^UKV>!-C_J3"U_ZLS9
M#] ?/"7= -JN;_XE+3RZ:Y_;0Q-](G#7XF#NH;[M>W@2DUUR,SW]S\!T@08
MK!/708T$!2MH$?J(R"\IC\6/B; ]X>V46RM=U /VX1$OT0-7'@ 9"BA5A%</
MIC]B1_P8QU&Q8#)P<:MX'MB2\'S'!M[+IXK?X"\MB_<=R9WI.8 '@!6/R_@0
MU#IZM*3>CNP#6/;8#,;T<P% ]*?,$[ 7J:_@$D?]8XG1H,C  ]*/0.R-/P'J
MRZDAQ[C?V ?<OP%$< /=ASN#^]1'P%S4S>FAP(KOK2P%LZ'0;I<DH"A *OV
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M)PL$*)XL$*!XLD" XLD" 8HG"P0HGBP0H'BR0(#BR0(!BB<+!"B>+!"@>+)
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MZ]K-P;"C" 3L3K,W<-39;,>6PZV:5!'59!OX)%XK/HD(@$\B N"3B #X)"(
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M24\M$)D#,@>D) R*&@0O12EJ5V&81L?2,ZSSN_O@C>F>3"YGX;+!1G5#7MW
M6+>4!JN=+5)T.Z$&A0RB)O!2E*+,+*U'D8LB%T7NHT2NGG;(&Q*0]Q>_&6R%
MB$@E9MS*UWUA\%L"3"=5[; 4/5/;-"L$:X'WS,/#PA89UE U_5UG0L($LYJ"
M2E%"TB\,8E!E_4<RB4+?8,N#F9G#XS;S5QE4?6PT\L10@:I',C-_I'-<.UME
MUN!@'I8$E+H5_38TIJ/N<8U2E>D(S0ZIRG/M)&RQ4D=/B^/JVRA:8LI5'_DA
M)E0<'%3;2V:U.Y#&NA+R!N0-2$K*X@?2DQ'TI%_<P[#RCQNZ FS'8%.$YPM@
M)JHTJ(X[]D4]%B(&J.N7=66;YK450\V0-=035(J2D9D5'SQO$VE)%E0=C(#(
MB-GB['0-SF1$TM4UF;KC)+3.WO_X?:?_^K=ED-R;'!#AJC7FI=;48%.4E9QH
M.6C6S*1U+):5!Q7:(3*$9!M*29WCEE*K3$D=I"092NKK)V;;)E@A[R/W;F;T
M1!.>;8EN&>F\%'3+2$#IQ-:+(XI#M8S3EUY@2*#*W &KSF7HJ#TPDXY0S$J#
MJG?<5A>J4I*M5_ACBYC5T_;X=4J"B?&6!^H6TBP11[G+< _'UI$EFM>H!RV/
M&D-*43H:F-F]&MM=R0M9[+(K)63UZBDIA&S7"+OCS/>M,+DGD746)-ZI%TS)
M&&87QJ;;(NT^QH6E835 A4.*4>K')SM&ZE#VD7.*5&8.=@NS1B3 9&83+*>+
M>8SRW>2.VY1344+2+/VJ94P1R,H4N9F3L>?ZR=)ZZT;$=$ND>^3PI\JPZG60
M1TIY-W2,BU25MVBL0[4[J$/)>W704_%4'4IC4G(<['LO;XX@*4F)VJK\1F4/
M571E[C!)!*=(POE/K2:U0ZPX]+U)*:=(<:7?[-?&8.F7&BQ7 ;SH;BEQNY+G
M+]HO^T.OE'?4#7 _;&$9^YRS)KRQ_(!.8]#MIH=\ 5.ZDC$_@A8?P;<1=55%
MW6&O;S;J/EE^U45XE]]PY9P_38]<XNZ0LV&0?RG&O^S&H&.;S;]0]*J+NBAZ
M=99#6YH]HBC2E)Y;=L=L>D91I"KJTC_-1EW-15%U_PI-SWPXKW4IEBF09',Q
MBMQ@+)-3(W-XB7P;61C6/NB5\L4=_>+VQ9G#A ]U@[+3KAZ=>TPH/XH?U(41
M;FE1)Q>3U.>\Q6*N1^4SZ$5D_1V%H,C(#@'CZGP29&/UF)VA%]:UAZBB/#>,
M.X/ZP%A#RCZQY7K5:W3@/6W3BM-5VIP3[Z&P!.>*MLULUQ>R2@,_/P&=[M'(
M<@^>@-'%<@]I6+6Q0X>,/5TQJT_5(QE7>,Z/W3UNWS>5F8.-0].>RAQTIJ06
M]G>1A=4.>Q()25LI.WA*X;G:-LEOB1M,/,OU?0\B9E9$'DBPR#7&,MQ*P0XX
MTK#"(>E2+A"YO'1]SJ2Q=H7L =D#DM(A@UQ(3C6&EZ(DM2M^JM&Q]&R9]2:,
M%[XW-;A#EO"*8D]S:5@YJ&W(@*FOG3/',=71BR$365@-'.0-$H1D7*]>')2^
M)ZB.VY%/43HZ:>OG\.N9T*GW=R]R1^3!>+/#P4PM^62,ZH(>9(E;TD"U.%15
MMV&--:8A!D'DK314F61(R;QAZ;RDY;B&J<J4U,&VO#*$Y&AH?)S8Q;[=>MH?
MUXMO'I'K8J"K 2+&D*%+1AI6#B:Q2H!)LC. 6F?J&:<TM5X@;5MI[F#CW*!'
M*1B&D))S7*5:;5)"2I)P#>E7+/)W RR/#V$TBDC@HN6!#AE96/4QJ4*"LKH]
M[1ABKVU:G@B?5XJL07H<X7$#R(K24=LQC8XX^T";0YJ.T'J7R>ZLZ)FBZ)&&
M0X,+U%W_2QAY6(_.#1+DEO)Y:YB+)>7LU#%$;&@"R9%17F7V@(%2*29JG''/
M=4@<D"Z?THA6B928E6OUJ]BABKJ#GO&0:Y*XX\A+3(^'#)$MRH>.CEN/JRP'
MT9(M&FI^'#D&J#)_&")[D*$DQ]!V6)B))9^TAOVO91(/M N*V(X)1>AOW <2
MC+VPHD.OH<;( !O>R(*JAY$0&4&B7VY6VSCW+4^40.U)&NDQ#"(55S.-CKC2
MB*55LG34P2B(#!UI*&+[)I@A9Q%=(O8"TXV./B982!L=6! BHW_IYYAI&S>T
MD$?\D#/4$E**4E%5I9B>5,1#B,=MD*8R&1VY<D91.G+T*P<I"E@]38XW))Z'
M06Q\$3K.&),'%7)$&?5+/Y/#-FY6 8]S8 A4VL[&&G099<G,&G0'\YJEZ0B]
M>A((I5^8PS;"YKA9)!3RQEL<.&>PKKV)%>4>)]VJCIK*'JJJ<EY/=8EG7B)[
MD&4/F)LN0TB.>?UV^1 +K)>2IR04M#*DU&OI*&B+K>U-:H#U)G*G2?B ';!X
MGB4.(Y0&%8Y E_&AZ^2JX?=NF@^7GQHS,VL**O7(2'1Q,-,H09M$EHY^_'[@
MV,YK)*;=2/5WC83LD\> J&V/?"1?T!S)1"F&2FH**D7Y2J76H>.9]-2D7F+N
M!3('[9F#>0%'!TNKT"1!DP0G$_(SWD;N7W2YR/BJD#:VYJCII#;UN <?'][N
M:FAYM!WC-*:72#Q2F3T<N5F8JI34JVK4K2<EO<2<&)4IZ<A-BQ6EI&(EA09'
M<MKFSB<\\WTK3.Y)9%T%\,J[)49&6(-[C"-+Y],CWY11:?7+U+*-Z_'#&]>@
M<8)M10_:$&=@)!VU4<1*@PISH:4"]3KZ (N.BQW6B6 323C_J=6D9H45A[XW
M*643AS!>.LTCF"[]\LJ2SS<7E^<W-];%Y>75KV>W%U>7*: .NAMZQ*[$5;V>
MA[&7>"&E-N*[B?= 7L,EG#K-3F>^ =B1&Q-8@5[PZ)6TR25YN46+;'_4*&6+
M+Q=-*T> '[:PPWW.61.V7W[ MMUZ%HR6XSR5(F<_-O-8B82(JRCBM@=F(^Y!
M!?-+*B7E]WM2-2%4TR.7Z)9REAER+\6XEXUB%\6NDHC;<LQ&7,UET*:?$"60
MEH3LM% "H012$7';/;,15W,)).MBU^O,Q0+ Q[O@#^Y_?]'DH4]3^FQDO:57
M%I&K@"CI?K\[B/M]J^]]>R1W)W[4/C;)?7VMZIE'>U## 6.\FL%X1P#XF#!^
M,I^K88S5EFL[J,^!#]*Q5"\:LY&/'0'&U3D_R,>>UI#W 'ED>B&<TZI.UD2B
M/D3Y1'T8IX9$?0"36[4#[VEO*]H,0%C/%W>!EQ#Y"QZ%21+.]LK_VLZ")!93
M@A'Q;',9-B1YXF=A^%I!6Z97R_%A_AARJ3M7;,GV>S'FR/M0EG9U$\CFD,WI
M2/,[VEH93?/UQ$*D?*3\ P;O&;B-4G.V'EQ8O.E.Q/-M9M6M 67XI-H@N4#V
M%D#ODU96\[R<VS!Q?>O,]STW&!,K(@\D6-#5O6#L+R9D8KFC\.'I-KHLQ*KK
MMPYP'3HD2QT"##61/UMRJ1JM7MW3  _#&@Z3)8AT80I=M.T.TL4AE<4GB'(5
M\O40)"7=#_>" E86F,%;[49W@#H'ZAQ(%T6Z: _Z2!>H<VS#C\W4*Y2OR$<V
M,_10NJ)T1:HHG'_HH&Q%V;K5>.WLU6W&#)!TRE(D_RMQJ?*0%K*Q_QUV<TV9
M2KSO?KXAQ"+!Q JG%MM1;$W#R K"A,3-]6*[7%FC6*$#K]BLY?OJ39)[$9C-
M_RJ][=5/W!&]V$6R_2<;-WOH.[1;4E ZM1S'.BT4'^;^#UOV)O_]G=>>VIU!
MOS/I3*;33J=G#SOM_FC<(0/''HZ&K>[_]CK?I3^ZSV*&<_>.G(XBXGXY=:?T
ME#^Y_E=W&:_#8N8%Z:8Z0W:[+P:U@5S2[/N+W\^OK8O+M]LQJ29;O;B\/;^^
M9'TISSY8U^>_GE]^/K^QWOR/]<OYU2_79Y_^<?&6?OQ+KF]E78_R_N+ZYO;T
MWY_/KNF1+*?EM"V7TC?]"\5@Z^3SY=GG=Q>WY^^*I;0K/L3X0(%3T\W[[CPF
M/Z5_>3WQXKGO+G_R K8']J/7,S>ZHV@J*+V[6<S+@,2_7J%OL\516$2WQ9O%
MUTWV54'4\^_:@V9_N/WK5M-^Y'?M3N]1OZS<;+,W>-Q^<-6J53M-Q^GCJHK<
MEFJK#J56E6\R8:N1>K./]?78 V^M?+$?D3YZ6-@>4ZK+61'OJ$KRX>K3^3OK
M_/,U_5/)]AWWN]IW/.;F)=RQ9B#&]?G-K77UWOK/U?6'=TKBAX?X<7#\./]X
M?OW+Q>4OUL>SZW^=W]XHB1A_E"%&>=ZM;6\FWCYY'%R=9>U.<4H?C<*O>]2U
M*^=B R.W"E+Z']_9>OR>ED?^F_7VW@WN*M.\M]_Z 2*XM8<0T@32!-($T@32
MQ 9-Z*TXGGR\^/#AXNKR9I_Q:E7*HX9HP6K(Y/U845K1IS-SO)J3J+F?;T_Y
M,R,>(!X\ @^T.//F/;_,M,J7N.ZKV[,/5GG,_W!8@),=]<AX=!H#Q_!9/8BZ
M:J)NK]$:UCV)'8=\/&W483&[U(0SEQ0-']R;A1RL#@=T&IU^VVP.AL)73=1M
M-YP!3MC26A Y)D[8*IE'@L)72P[6:=2_!A:%+Z)NR0'[C7:O[H6J*'R?)(C:
M)8V2M#]S[V#C+7<<_E$3+COPCI<!S2\?KMZ<?;#>7%Q]^L?9]<>SM^>?;R_>
MGGVXL=Y\OKFX/+^YL4ZR+U\]"V=X[BS8T4&F7^;O'4,4>D@[I]'KU;W-(BIJ
MB+HE!^PVAJVNV:BKN]+2-=!+TG702V((!W,:G:YM-@=#X:LFZK8;#GI)]!9$
M&*) X:LQ!^LT.K4?O('"%U&W/$311LM7:T%D9(BBJ' <-$3!,*W?['?KS;P^
M1=[,C9;66S?:8Q09NNO-X/QVH^<8SOD1==5$W4ZCW\:D1JT%>*^88V#"F=OH
M,3"$@]F-P1#=]2A\%41=I]'M&(ZZN@LBQT#A:Y?,#$'AJRD'&[:PG ^%KX*H
MVVT,3"^&T5T0E=65ZW[FC8%=CW?7EZ*9[32=VCCKM\PI<K_YX8,W>=K5[YYK
M(-55<C?G?T'.6 Z_=J__6.9T<,ZD*XP=NU<;&#^*&=2%#9:#M]_:F FL\W$'
MSO;C'J(SL(($UFT/:T-@NC(Q>]"N#8PUI.J_F\3"MA_64 9F-YR64QORTI6%
M=5$-0P[V'(?=878?H%)?S&8%P,$DV;7"?=MF5OK+ .)M./.BP$V6UL2+R)B^
MWH4YU#"UUO5]SPW&Q(K( PD6)%:R<'\L7[B_AQ-!0>8YK.:>SR>$U(-5NS%H
M#8X*+2EF4S\V>C*0ZX"JV*%*$I+VUW#50WN[83L=9!*R7L%&:X?O=2>T*K4'
M;<BI(Y=6H=:A*JM+M.81+;N+/$)6Z6JTVJA(2,G<EH9,8N-0^QF:JL1PSWWO
MSX47;QJ,S(S,VY6'F(JF,C]H[PAT(._,P:I_7#FC*I.Q=>2<56:EQMI5OSJ(
M@.PAIXC:U?%,9 ];NM;J<"BG)&O=!/[@M&QD$+*P.K(O2U5:TE)_V+-5]Z%[
M<;]H2.\3-;\"-[+XVDH&[288M.-*3@<50FE8M8\+*T598U\FV5:I$]G= R34
MJH?O PS528/JN%XW1>GH1*Y;J5)G,I,U.$,T$^5=\BUD#C)F8DE3?>4/5>Q5
MK&=\[G(1)61L7;V[_?'[3O_UK\O)(G)-#\7]^/W L9W7R"=K#"]%V8H E6[<
M<M>Q-%:HD%G4'UZ:4I6FQ]*861PW+JTRFSBNE:HH)<G4Y2E\(#U-KD\1F;F1
M%Q2"<&AL(6.L*[P4Y2:H/^FF/V%<2SJZ@0Q"PLGKZ.BYMJN"=1HS!ZP]JZ<9
MJB@==2H"Q(H>J5OH+Z>G@?7FXR<'K2JTJNH.+T69"%I5NBE.R"SJ#R]-J4K3
M8R&S0&:!S *9Q=9CZ6EYO;_Y>'YZ\?'CYTN637CKC<-?W;'IMA@V]MBCL0?R
M20G/E':.*;MBS@/J4L@>4)="7<ITPPM[--<S$*@H)=GZ57L[;1/"6Y=TK2#R
MOIEN5CG'+<Y4&E38[D@J<::J<;.RAS*T8SVJ2_6$E*ITI&$'#(.-*6Q4+^]M
M1)^L#'_H5?4=5?901:ZGITEUYOM6F-R3R/H4>3,W6EIOW8B8;F#9#G88E._&
MB":6E#6BH1I5W2978R6JAZW$I%MK8IM!&4IR=)P9:&H]EMW#<DWY: P&K:0,
M$OWX0V>OH%7%F.TBETCQI-_LU\;^ZI>"X&9.QI[K)])VER04BF;9_C LY1YU
M ]\/^T^]WSAG3;AC^0%[W>&SS"J0=9-6,.9'T.,C^#8BKJ*(.^B;C;A/EF!U
MD=WE]ULYC$[/(SL;:4-R]@OR+L5X5QN%+@I=%1&W,QR8C;B:2Z#J$8^ZGMG>
M/#,*7BWYE]VPG:[9' Q%KZJHV^H8CKJ:"Z*!3-6(3@<NULD\WC]?=6[U1LG^
MN@PF[I_$5WF6+)&?)2MSKQ)98++HH4;4TG&J<T/W((8#1G_U@K&]8T+E,6'\
M9#97O^BK4]%Y0,?C5E1]2J>BZ$5@W>K,"^1AA\B.K>XXC#SLB5DQ<FW,]3EP
MMRH/R% ^MJ,>&OG8LU>-(1M[XFAJHU2Q3LN$;A4W"W].(O>O,#"]G J;?=4?
M7HJF$&.S+]UJ)Y!9[*F9(9N0,)OZ.E9?]DLR(TQ@$6UL@+6';8SUES*NT+9V
M/0%[71.LK-^(_X<;_&6ZB=7%AA4UK=U7E'N<V#H6I%>U.=1883IR(ROD#MIS
M!Z>JMZ:JAZID>3JSAP&RAWIR4D4IR=;.F!J:8$N=!Z.(^-;)U2*)O0FQDGMB
M?6[>-"TWF%AOW<"=N/LP?2T-K3[R2FDN8..T=1FUHUW51$_50SD'R5-2#^G;
MV%Y9VM0ZKA=?54KJR*4XJG6HMJ&= 0<XG$%^,B+:6E*25D?UP2XR/3TMKHM@
MZI-Q$KFFFU4.\D7Y[ =DBS(<1,>I%*:.M&ICPH\T)\4 EHP?7ZKX5:TC532H
MT)DU(&>H):04I2*I2BRE3F3OUV9=44OJ=R^YC^@J.!P81]-(TSHRQ-U ^KMN
M_'#[@336DC J54](*4I#)W95Z9&BAZK(6M*8,]@.SJJ2SVC!D+4,F/0KIG+:
M)AA1OY @3*)P[AG?LF)'>T=DBB\&*D49B*:-*@[15%%!E$>5J::@4I2,3G0T
MI\RTIYSC>A65Y@V8R2(3MM//FNHZ3[&FI"VH6DX/N+BS/H51,@U]+U1R=,!4
M?G2 UB8B-BJK/[P4Y8^:&HO8U1"918WAI2E5:7HL9!;(+)!9(+/8>BP]0W2_
MNP_>F.X)*\8P0B<-JN/V+%&4AYQHV"+:3!<\9D"CYH1YT(\_D,:L8<=(4>0-
MN=2.XY;D*TI%Q2'9&ARI.(U,3T/J#0G(^XO?3#>C;%26#C0#$1FBZ$>D8^-X
MV]#.\4=NX:DT>\!,1QE*JNH+JNB9'".]+-BR"Q,=#SRJ3#M3JCTPP93Z2"91
MZ!MO26&-/:I*!\V2UHX=VF9J2NASKB>D%*6B$PT[FYK)&(Z<F*$R9SBRM:DH
M&6FH,M@F6%!7WT;1$G/Z,/&Y_O!2E(\8E/ALB/*$S*+^\-*4JC0]%C(+9!;(
M+)!9&%92=4-7@.V8;GVA-TH^KHM#=J2RYG0<36CHY%)L>8@=Y ])1E4)M:J>
MJ:J+H\:L 1-?ZLE$%26C=D75LJ)'ZG1-B&)=DZD[3D+K[/V/WW?ZKW];!LF]
M\3$M&_M48)HT%EAA@54=- *5N0/J3E)TI&%]5?6T,8V9 \Z9J.O84T4IJ2H!
M7]$C.4:46+V/W+L9CN5JHZM)&E0XEDM&M=!073*SEN+(HSE59@TV^EFDK X-
MZZQ.[+:9IA0VLMFC#P.R!PE*:FO8+_BD7?2TZ&E._3HEP<1X8PHY(KJ>#\D[
M=,SV<PQ-]T-SJJXM5%6EI$K+0]5#.69RAR,[%U7F#AWL:6-N4DO1@Z2G-77F
M^U:8W)/(.@L2[]0+IF0, X5CTRVL'K9(E9XV@3YI&8ZB8]6$H1YI!_TO-9WU
MIRHAV3KJ4*;Z7WIH8LF76*"#5H:4-&0/'1.2_U;VU<V<C#W73Y;66S<BIIM7
M#F8#2COLT+R2\D)5%1JH>BC;4!5JB*/MY*-]F/-CJOO%T!"6W4(#2WY>"[('
M*5+2,<2];Q!+<(HDG/_4:E++RHI#WYN4<HH45_K-?FU,L'XI%*X">-'=4N)V
M)<]?M,CVAUXI[Z@;X'[8PC+V.6=->&/Y =N#5GK$%Z#.2K;\"$I\!-=&Q%43
M<3L#QVS$?;+LJHO@+K]?66>&5F<N:W\A9\$@_U*,?SDMVVS^A8)74<1U!F8C
MKO9"J,JEINN94>X:PKXZ;</M!I2[BB*N;;BG1G,9)#7\5*<#V^V]LI\JCEZ*
M80ID1EV,(C<8RR1"R1Q>(DE*%H:*Q/5V)$[NBS&'B8_J!6.G73U6Z9@P?A0O
MJ L/W!9S[3_5V%+MP =)V-"+R ;5F:#(QPZ1+U-=S/@D&%?J%690M5SS%'T.
M?)!^_YJ1V([VMLC&#I'*5IT5C.K8,6J,M#FO8T+]T47@+Q/C!SGML.,P7S@'
M*AR!*0&EOG:S&.R.F:W'L<V+-*BP&]8!K4&U#E4Y#5QC]M#%.D1IQ0'9@XS1
M,=1.<V@;,2#WM\0-)I[E^KX'84LK(@\D6&"?O!^_'SBV\QK99(WAI2AC$:#2
MC5_N.I;&ZA0RB_K#2U.JTO18R"R062"S0&:Q]5AZ6F-OPGCA>U/3C2_L0UQ7
M4"G*02H[2BEZ)D,#6]A@4SZ5'EF#3 Q(PP:;;2-Y W;/DYX"@YQA-Y#T"VDY
M^U7G*6I$_>Y%[H@\&&]$X;A,:5 =-X]24>YQXA3;;FIQ*$-G/6'J<$WG#JM*
M2&5][I0_5-69-&8.Z'^M)Z14)2.Y@GBESF2$*76]^.81N6XF6MM2Z%F2CDH@
M/Y1 )T<[U]*@XD@:*TI89E5/2"E*13WM^()=<22-^0(J#-((@GQA-Y#^KAM;
M^+L!QM.',!I%)#"^2X6-KN::ENTKRCQL6S\U:6"DFF1C';IT-@IR!@E\JDA\
M4_1(CID&U)&GPZO,&3!Y!2TH/2VHWUS_2QAY:$ A+Y25EL<5&XKRCA.[JM6Q
MLH>J:O2JL:J$W $S^0Y+2#KF^5:=26/FT,5(E'3,#KF#N;I#L0I 3X/JFB3N
M./(2TRTJK(W"]LC/.71!@Q-55+]JK"YA<Z[ZPTM1@C*H.9<AS *#U\@F,%"%
M@:KO?G[C/I!@[(781WU#,<9^7=*@PE1H*2AI9VHY9B;_H1,&6_D=K=9(T2.U
MS2RK/*[/467.@&,M92)[^LVU'/1-Z#]Q%M$E8B\PW8K",O-Z0DI1YB$Y$EVI
M,U68A1HK2NB"EK8VD3%(, 9'Q^2>RM'%&C.''II1TF84]JV2X:'ZM41O#TVP
MH]Z0>!X&L?&M*+!4HIX>.$691V51@:IGJAJ5I;&RA'42R!H.2D9=#7E#98]W
MC9D#Z@W8__>0'+1B=J.B1S(AR^]FD5"XFVY#84*?M&\!$_JDC"@-HU$G T/'
M2F%'/WE0H:XD94AI.)]WL][<$/;@8":+M)Z%?A892NKJ.':N6^1Y>AI4;R)W
MFH0/QC?XPZKS^L-+45:"5>?:J5#()I!-8-7YHP^D,6M /:+^\%*4G@S2(_2T
MM3Z2+VAJ(8M4 5X:\1(#CJ6Q/H6Q+&03:&JAJ543A$<&802#,$B/T-/4NHW<
MO^ARD?'E5EA_BI-IL-YJQYE,S01"WE!+2"E*1OH-8*B:9:PQ7[#;R!A0:3AD
M%49%=UU%C]0QHFG%F>];87)/(NLJ@%?>+4VWI["X INI'[@1H(X65:>J]%YC
MU0FKU+%+Z"%9J'Y=D]M=M*F0,]1(Q5*4CAS]W"WMSEXVE> 123C_J=6DAI05
MA[XW*>41]AYFUL1[*$"/LZ$.O..Y =,O+]+Z?'-Q>7YS8UU<7E[]>G9[<769
M NJ@NZ%'[$K<U.MY&'N)%U)2([Z;> _D-5S"J=/L=.8;@!VY,8$5J%8X6NF$
M%,J5B"MYN44;<W_4*.6)+V>'ER/ #UMXX3[GK G/+S^@W>T_"T;+QL4KY,U^
M;.:QX@@15U'$'73-1MR#"N:7U$G*[_?$EFLBJ->92_I]R!EFR+\4XU].VVSV
MA7)73;RUAV;CK>8BR)8:<Z#3B8O.#Q2YNK(NIV4VZT*1JR;>M@U7%3470"=M
MN<%C6IVY4YQ+]OB8P\$##K;-\L->)A;S:4J?C:RW],HB<A40)>,-=P>)-VP-
M-FR/6^_$#T4BL=WJD2Q[4,,!(]J:P7A0W<W]F#!^,I^K7TSY /Y;U0Y<U:Q9
M.L-&+R)SJK-OD(\=@(]55YH^"<25ZI,)1/UD=YA:QRWQA1G/P:H+C9"#'0#K
MZB,D-*3I [@7%#OPOKX%16O$A*?@XB[P$B)_P:,P2<+97LE]VSF0Q&+J\"&9
M/CW[G?M9N#["_/B.9OEWUYLWRO=7,NS@^U"9=C4R]21"9'S(^)#Q(>,SC@B1
M\2'C0\;WC#TWTYV(Y]O,V,T#I2/E:LN#9,UDELMEV +H??(*:YZ9=1LFKF^=
M^;[G!F-B1>2!! NZNA>,_<6$3"QW%#X\W74A"['JFL4#7(<.Z7*' $--Y,^6
M;+I^K^;I=(=A#(?)$D6J,(,J^GT;J>*0BN(3Q'@-TS4WAO(B2,K:A^T%!JPK
M,8.U#E'?0'T#B:+8E@NI O6-[24QQ10.!(FSLS<$ZAO(6D'?0,:*Z@;21*$E
M-A(%:AM;O1L]U#:*WHU.60[M?R4NU1S2JLY<_:SX<0=29C>+1K]ZD^3^)[L%
M*^=_E4)R]1-W1(&V2+;_9 -JAX:/W9*BZ5/+:5NGA2K7W/]AR][DO[_SVE.[
M,^AW)IW)=-KI].QAI]T?C3MDX-C#T;#5_=]^^[OT1_=99'+NWI'3443<+Z?N
ME)[R)]?_ZB[C=5C,O"#=5,=I]@'VV\ V<Z,[^K0 ^) ^*3X!;.UEM<X__[\1
MW/+FH8YY P.Y[.?W%[^?7UL7EV^;ZQNNWU8OKV[/;ZS;*^OZ_-?SR\_P][,W
M'\[IWM]?77]<ZRI;UR.<?+X\^_SNXO;\W:N-K5)V"5RAP"7IQGQW'I.?TK^\
MGGCQW'>7/WD!6Y_]Z/4Z8G8WJ\H9 /C7*^QNMCB&BQB[>+/XNLF^*HA9_IW3
M;'<&6[]M->VMWU6M.NPV.UU':MGR! 3;WLA Z%5/==FOHF&G0D"YP O5:KA/
M',%1IF@_QVF:,OT2THR'"R#4P 6)1O\5D7E$8DJ\L?6./! _G).)=;Z(Z)_T
MNSOZD/5_<]]<DSBQPJGUGS#R)ZL'SF<$*.7.^NA&7PA=BW_3I+],7,^/K6D8
M6<D]?9'X)K;<B%@3$H\C;T37]0+Z2)@$84+/>W+_RDI"Z^2/5]:(OO=K@_XH
MGI,QB&M_V2Q+FE$?UT;/AFM;)6W[&=J(2*+B?XA%%Z%ZA!4N(GK2&46@L4?Q
MD6)9Q' SIO@2A8N[>ROY&J8?4PR+R=T,T+5A$7=\;_D4>49+R[5B^J6?KAK]
M^'UW\-IZXX7S>S>:N0WV&B\(P@>F]%GQV"/!F&HQ;@P+I,^-R8+!SQHMZ'HD
MIF]Q@XGU1OR+T@Y?(0S@B\U=690\J.3PXGN.TQ3EK:D749KY<^%&E.Z =IP6
MU<Z2>S=)4XUBJ]A7Q3KY]-9^U6"_I\"A6+!D&6/]U[%UYX<CNL,QA7'DCA-*
M1(PXV>MALQ0"BRG]8A'!QL+HS@V\O]B>V=<N!9D[87M>S.>^Q_<$Y$7!GU!(
M,C*S"O"@ST=DXG' PS)K]5WT(TJBH +X2\MW%\$8SA].IX3O@:Y/]YI0RA];
M=PMOPA*N8!423*B2=TK_L*Y__+X]>/V.0C)Z\,84)I0#Q,2G5)^_-WI3":'7
MSH'BP6, 2(;NUE<ON1<;RZ"5+CL-QPO&=-RX:;VA.PD"V)JXH^3>BR:%.W(:
MUE? IPG%%@KB") S!TRX@GLWN.,[G2XB-A"-'C.(*;.;,83+(W-(>5D"J_ML
M,8'YY-L<2);R1;J3,?VK2_]DNV3P@7\$] :\.;] NK,Y!0#]B+Y^NJ!W3*R
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M/$DHM%!9;B+O_KK/8@A)-(ZSITP95 MJRTGC,=0V;XAE F7^Y%'^['HL1MF
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M"[P0#QCWC:J*5-;54?K^TJ/I@'L[_RQE5?<^)","\MZ.*]! _G?>SDIKW+/
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MXSQ&M%^6RODXWZUJCU\SV?LP(3XZ#3VNHE#SY.=F^PE%U5GLI8 0'@<=AT5
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M;2%Z:?*[Y4B6YPZ$\"QP6EW9;?O(XPPV)V!7L2,ZA5^#-/#W_@=02P,$%
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MP(13!&]RN5/HWC,V6,QN<F,S6#>V<1?E[UE2%&I19OEWB]4J7S[U@Q )(F+
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MR>8W<6%>O7VQ?B=9_M/2MR_^!U!+ P04    " "Y0*)6PF3KK @(  "9/@
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M\9 HH4%07!9-(OC $VH"!J& &_48!-DWH??ZVM(5";!HFYLK/Y#XK3.;0V3
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MH?O3_9;YU;/_ 5!+ 0(4 Q0    ( +E HE:)T2DII,4  &4I#0 5
M      "  0    !P9F4M,#0P,C(P,C-X97@Y.2YH=&U02P$"% ,4    " "Y
M0*)6"6/+=187  ".M@  $               @ '7Q0  <&9E+3(P,C,P-3 R
M+FAT;5!+ 0(4 Q0    ( +E HE:E#=[O(P,  *T*   0              "
M 1O=  !P9F4M,C R,S U,#(N>'-D4$L! A0#%     @ N4"B5N3C:#YV"
M+SP  !0              ( !;.   '!F92TR,#(S,#4P,E]D968N>&UL4$L!
M A0#%     @ N4"B5@=GN3[E#   @G8  !0              ( !%.D  '!F
M92TR,#(S,#4P,E]L86(N>&UL4$L! A0#%     @ N4"B5L)DZZP("   F3X
M !0              ( !*_8  '!F92TR,#(S,#4P,E]P<F4N>&UL4$L%!@
0   &  8 A0$  &7^      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
